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ABSTRACT
Natural products are a rich source of medicinally important molecules. Monoterpene indole
alkaloids from plants are an especially important source of therapeutic molecules. Due to the
complexity of these molecules, biosynthesis of derivatives is an attractive way of obtaining
molecules with potentially new or improved functionality. The rational design of mutants with
altered/expanded substrate scope is an important step in engineering organisms to produce such
compounds.
In monoterpene indole alkaloid biosynthesis, the enzyme strictosidine synthase catalyzes the first
committed reaction. This reaction is a Pictet-Spengler coupling between tryptamine and
secologanin and produces the biosynthetic intermediate strictosidine, common to all
monoterpene indole alkaloids. To better understand the structural features that impart binding
selectivity, crystallization studies of this enzyme were performed. The native enzyme and
several interesting mutants were studied; co-crystallization experiments with inhibitors and
substrates were also performed. Diffraction quality crystals of the native enzyme were obtained
following optimization by grid screening, additive screens, and macroseeding. Data on the
optimized crystals was collected at the Argonne National Labs synchrotron radiation source.
In addition to monoterpene indole alkaloids, the benzylisoquinoline alkaloids are another class of
medicinally important plant derived natural products. In a reaction analogous to that catalyzed
by strictosidine synthase, the first committed step of benzylisoquinoline biosynthesis is a Pictet-
Spengler reaction between 4-hydroxyphenylactetaldehyde and dopamine, catalyzed by the
enzyme norcoclaurine synthase. Two different forms of this enzyme have been identified,
neither of which shows any homology to strictosidine synthase. Structural information for these
enzymes could provide general structural features required for enzymatic Pictet-Spengler
reactions. Before crystallization, the enzymes were expressed and tested for activity. Once
active preparations of protein were available, crystallization studies were performed and crystals
were obtained.
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1. Introduction
1.1 Medicinal Natural Products
Natural products provide a rich source of bioactive molecules used for treating a wide
range of different human diseases.' Even in light of new methodologies for screening large,
diversity oriented small molecule libraries, natural products still provide a large number of lead
compounds used for developing new drugs. In a testament to the continuing utility of natural
products, most combinatorial libraries rely on the combination of structural scaffolds and
modifiers derived from natural products.2 In an analysis of 1010 new chemical entities (NCEs)
from 1981-2006, Newman and Cragg found that 43 were natural products (4.2%), 232 were
derived from natural products by semi-synthesis (22.9%), 108 were synthetically made natural
Figure 1.1 - Medicinally relevant natural products.
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product mimics (10.6%), 47 were synthetic with the pharmacophore derived from a natural
product (4.6%), and 107 were synthetic natural product mimics with the pharmacophore from a
" "
natural product (10.5%).' In total, more than half of the NCEs were derived from or inspired by
natural products.
Medicinal natural products come from a wide array of natural product classes and exhibit
a staggering array of structural diversity. Some of the classes that have yielded natural product
drugs include aromatic polyketides, polyethers, coumarins, flavonoids, terpenoids, alkaloids,
nonribosomal peptides, and aminoglycosides.3 A sampling of relevant medicinal natural
products can be seen in Figure 1.1.
1.1.1 Biosynthetic Pathways to Modified Natural Products
Making modified natural products is an important way of obtaining new drugs.
However, synthesis of these modified compounds is in many cases a technically challenging task
due to the structural complexity of the molecules involved. Total synthesis of modified
compounds is not an optimal solution, since these syntheses are often complicated and give very
low yields of product. In view of these difficulties, biosynthetic pathways to modified natural
products seem to be an attractive way to investigate new functionality with potential to scale up
the production to industrial scales. In a recent review, several different biosynthetic approaches
to modified natural products were detailed, including precursor directed biosynthesis and
mutational biosynthesis.4
In precursor directed biosynthesis (PDB), modified starting materials are fed to wild-type
organisms. Any modified natural products are then isolated and characterized. While no genetic
manipulations are necessary, this strategy is limited by the ability of the producer organism
biosynthetic pathway to accept the modified starting material and incorporate the modified
products in downstream steps in the production pathway. Another biosynthetic approach to
modified natural products is mutational biosynthesis (MBS), or mutasynthesis, to use the
terminology of Rinehart. 5 This strategy involves the creation of mutant enzymes which are then
supplemented to the producing organism. These mutants are selected so that they incorporate
non-native substrates into the biosynthetic pathway. As with PDB, any modified natural
products produced can be isolated from cultures, characterized, and assayed for new or improved
activity.
1.2 Monoterpene Indole Alkaloids
Alkaloids compose one of the largest and most structurally diverse classes of secondary
metabolite natural products. These compounds are defined by the presence of a basic nitrogen
atom (the term "alkaloid" comes from "alkali"); the different alkaloid classes can be
differentiated based on the source of the nitrogen atom or the structural scaffold present in the
final product.6 The source is usually an amino acid, including both proteinogenic amino acids
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Figure 1.2 - A selection of biologically active monoterpene indole alkaloids
(i.e. lysine, tryptophan, and tyrosine) and non-proteinogenic amino acids (i.e. ornithine).3
Alkaloids are produced by an array of different organisms, including plants, animals, bacteria,
and fungi. Due to the prevalence of the use of plants in traditional therapies for a large number
of illnesses, plant alkaloids include some of the most historically important pharmaceutical
compounds.7
The monoterpene indole alkaloids (MIAs) are one major class of alkaloids, so named due
to the presence of an indole (derived from tryptophan) and a monoterpene (secologanin, itself a
complex secondary metabolite).8 There are approximately 2000 members of this class of natural
products, and they display remarkable structural diversity
Figure 1.3 - Vinblastine and
and a myriad of different biological activities. 9'"o Figure vinflunine.
1.2 shows a selection of MIAs and their associated
medicinal uses.
Most notable in this selection are the Vinca
alkaloids vincristine and vinblastine, anti-cancer Vinblastine
compounds from Catharanthus roseus. The Vinca
alkaloids are used to treat leukemia, lymphomas, and
several solid tumors." They have been shown to arrest
Vinflunine
the cell cycle by destabilizing microtubules, and have
been implicated in apoptosis mediated by an NF-KB mediated signaling pathway." Also notable
is that a recent semi-synthetic derivative, vinflunine (shown in Figure 1.3), has been shown to
have improved activity and act through a novel mechanism.12 In addition to demonstrating the
importance of MIAs in medical treatment, the new findings regarding vinflunine demonstrate the
ability of modification to impart new and interesting activities.
1.2.1 Biosynthesis of Monoterpene Indole Alkaloids
In many ways, studying the biosynthesis of secondary metabolites in plants is a daunting
prospect. Unlike bacteria and fungi, the biosynthetic genes encoding plant natural products are
not clustered. Instead of identifying a single gene and being able to find the rest of the enzymes
in a particular pathway by sequencing genomic DNA on either side of the initial hit, each
enzyme in a plant biosynthetic pathway must be identified, cloned, and isolated individually. 13
Scheme 1.1 - Initial steps in MIA biosynthesis.
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Within the group of MIAs, there are several different subclasses of alkaloids that have
common structural features. The abundance of these different subtypes varies between producer
organisms that include Rauwolfia serpentina, Catharanthus roseus, Ophiorrhiza pumila, and the
Cinchona species.8 From these diverse subclasses, it is clear that in different organisms the
biosynthesis of MIAs can follow various different branching pathways. However, the MIAs are
united by their common precursors (tryptamine and secologanin) and a common committed
enzymatic step. This step is the coupling of tryptamine and secologanin through a stereospecfic
Pictet-Spengler reaction catalyzed by the enzyme strictosidine synthase (STS). 14 Tryptamine is
derived from the amino acid tryptophan by an enzymatic decarboxylation catalyzed by
tryptophan decarboxylase and secologanin is itself a terpenoid natural product thought to be
derived from the non-mevalonate pathway.'15 16 The f3-carboline produced by STS is known as
strictosidine, and is the common intermediate in MIA biosynthesis. This first reaction step is
common of all MIAs, regardless of their eventual final structures. These initial steps are
illustrated in Scheme 1.1.
After this initial coupling step, another common (but not ubiquitous) feature of MIA
biosynthesis is the deglycosylation of strictosidine by the enzyme strictosidine glucosidase
(SGD).' 7 The glucose moiety serves multiple functions in secologanin and strictosidine. These
functions include recognition and proper positioning of secologanin in the STS active site. The
glucose also acts as a protecting group in the strictosidine product. Removal of the glucose
reveals a reactive intermediate that can undergo spontaneous rearrangement to give 4,21-
dehydrogeissoschizine.' 8 This intermediate can be converted into a range of alkaloid structures
from the different subclasses. An interesting exception to this general pathway can be seen in
the biosynthesis of the quinoline alkaloid camptothecin. 19 In addition to a rearrangement of the
indole ring system
Scheme 1.2 - Deglycosylation reveals a reactive intermediate.
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into a quinoline system, following STS the first step of camptothecin biosynthesis is formation of
strictosamide by attack of the 13-carboline nitrogen on the methyl ester of secologanin. It is
currently not known whether the biosynthetic pathway for the other quinoline MIA, quinine,
features a similar first step.8 The degree to which the enzymes involved in the downstream
biosynthetic steps are characterized varies based on the particular pathway, although feeding
studies have been useful in identifying plausible intermediates.
1.3 Strictosidine Synthase
Strictosidine synthase is a Pictet-Spenglerase that catalyzes the stereoselective coupling
of tryptamine and secologanin to give the 13-carboline product strictosidine. It is a 344 amino
acid protein and contains no metal or cofactors. As described above, STS represents the first
committed step in MIA biosynthesis. Due to its central role in the synthesis of a number of
medicinally important alkaloids, early efforts were made to identify and clone STS. These
efforts are described in an excellent review by T.M. Kutchan.20 STS was identified by traditional
reverse genetic methods, meaning that the isolation of the enzyme preceded the isolation of the
gene. STS was initially purified and characterized using cell-free extracts from C. roseus and R.
serpentina cell suspension cultures.2 1,22 Once cDNA libraries for producing organism became
available, the gene for STS was isolated from both C. roseus and R. serpentina.23' 24 STS has
since been cultured and expressed in a variety of heterologous systems, including E. coli and S.
cerevisiae.25 Notably, STS from C. roseus and R. serpentina features a predicted signal peptide
used for intracellular localization. This must be removed before active protein may be obtained
from heterologous systems.
1.3.1 Reaction mechanism of strictosidine synthase
The Pictet-Spengler reaction is a general reaction between aldehydes and electron rich
aromatic amines that involves two basic steps. 26',27 The first is the condensation of the amine and
the aldehyde to form an iminium species. The electrophilic carbon of the iminium is then subject
to attack by the aromatic ring in a classical electrophilic aromatic substitution reaction. The final
intermediate species is deprotonated to restore aromaticity and complete the reaction sequence.
The enzymatic Pictet-Spengler reaction has been kinetically characterized from several different
species (including R. serpentina and C. roseus), and the mechanism of C. roseus STS has been
studied in detail.28
In the Pictet-Spengler reaction between tryptamine and secologanin, a chiral center is
formed in the product and as such there are two possible stereoisomeric products - strictosidine
(S configuration) and vincoside (R configuration). In model chemical reaction systems, both
strictosidine and vincoside are produced, however in the enzyme catalyzed system strictosidine
is produced asymmetrically. The initially proposed mechanism for STS involved several
acid/base catalyzed steps. An X-ray crystal structure of STS from R. serpentina suggested that
Glu309 (R. serpentina sequence numbering) was the most likely residue for this catalytic proton
shuttle.29 Indeed, mutagenesis of this residue to an alanine resulted in the greatest loss of activity
seen for a number of different active site mutants which were tested. 29
Kinetic analysis of the mechanism of STS was performed by using kinetic isotope effects
determined with deuterium labeled tryptamine substrates.28 The data from these reactions
showed that the rate-determining step of the reaction was the final deprotonation to reform
aromaticity. While this may seem counter-intuitive at first, it is important to note that following
the electrophilic aromatic substitution, both the forward reaction (to 3-carboline product) and the
reverse reaction (to the iminium precursor) would accomplish the energetically favorable
reformation of aromaticity. As such, the rate of the reverse reaction is substantial, slowing the
rate of the forward reaction enough to make it the rate-limiting step. This is a rare occurrence,
but is not unprecedented. 30'3' In addition to the kinetic isotope effects, detailed analysis of the
pH dependence of the reaction catalyzed by STS shows multiple different acid and base
catalyzed steps, thought to be the different proton transfers mediated by Glu309.28 The current
mechanistic proposal for the mechanism of STS is shown in Scheme 1.3.
Scheme 1.3 - Mechanism of the enzymatic Pictet-Spengler reaction catalyzed by STS.
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1.3.2 Crystal structure of R. serpentina strictosidine synthase
The crystallization of strictosidine synthase from R. serpentina was first reported in 2004,
crystallization of the enzyme in complex with tryptamine was reported in 2005, and the structure
of R. serpentina STS (rsSTS) was reported in 2006.29, 32-33 Three structures were reported - the
native protein (PDB 2FP8) and the protein in complex with each of its substrates individually
(PDB 2FPB, PDB 2FPC for tryptamine and secologanin, respectively). The structure of the
native protein is at 2.3 A resolution, while the complexes with tryptamine and secologanin are at
2.8 and 3.0 A resolution, respectively. Phases were obtained using Se-Met derived protein and
MAD phasing. Due to the small number of methionine residues present in rsSTS (only two in
the native protein), suitable phases could only be obtained after several Leu and Ile residues were
mutates to Met. The best results were obtained from a 4-Met derivative (L 116M, 11 90M).
The crystal structure of rsSTS revealed a six-bladed four-stranded 3-propeller fold,
shown in Figure 1.4.29 The six blades of the propeller are roughly arranged in a six-fold axis
around the center of the protein. The blades are composed of four twisted antiparallel P-sheets.
The structure is primarily P-sheet, but there are a few small a-helices, one of which is joined by
a disulfide bond between two cysteine residues. There are two molecules in the asymmetric unit
and the interfacial area between the two molecules is 1937 A2. This contact surface is fairly
substantial and may be suggestive of a dimer, however there is evidence from size exclusion
chromatography that STS is stable and acts as a monomer in solution.22
Figure 1.4 - X-ray crystal structure of STS. Each 1-sheet is shown in a different color (1-6);
a-helices are shown in orange (a-c). The active site is in the central cavity (PDB 2FP8).
6
The active site of rsSTS is found in the center of the rough barrel formed by the six 1-
propellers, and is a pocket lined mostly with hydrophobic residues. Tryptamine binds deeper in
the pocket than secologanin with the amino group positioned proximally to Glu309, one of the
40
few hydrophilic residues and the essential catalytic residue involved in acid/base chemistry in the
active site. In addition to being surrounded by hydrophobic residues, the aromatic indole ring of
tryptamine is surrounded by the aromatic rings of Phe226 and Tyrl 51. These aromatic residues
may help to stabilize the positively charged intermediates formed during the course of the
reaction. Secologanin binds in an extended conformation, with the aldehyde pointing in to the
pocket located near the catalytic Glu309. The terpenoid ring is in the in the middle and the
glucose is sticking out of the pocket. The glucose is solvent accessible and makes several
important contacts with His307.
1.5 - Active site contacts made by substrates. Tryptamine binds deeper in the pocket than
secologanin. a) Tryptamine binding (PDB 2FPB) b) Secologanin binding (PDB 2FPC)
This initial structure suggested important roles for several active site residues in binding
and catalysis. These roles were probed by making mutants at the residues in questions and
performing steady-state kinetic analysis of the resulting enzymes.29 Three mutants were made -
Y151F, H307A, and E309A. As expected, the Y151F mutant showed decreased affinity for
tryptamine (-3 fold less than wild type), unchanged affinity for secologanin, and only slightly
reduced catalysis. The H307A mutant showed unchanged affinity for tryptamine, but
dramatically reduced affinity for secologanin (-130 fold less than wild type) and catalysis. The
drop in catalysis may be due to conformation changes in the active site caused by making such a
substantial mutation so close to the catalytic residue. Finally, the E309A mutant showed
unchanged affinity for tryptamine, slightly decreased affinity for secologanin, and almost not
catalytic activity. This makes sense in light of its validated mechanistic role in the acid/base
catalysis of STS.28
One of the ways of further probing the active site of enzymes is through crystallization
and analysis of structures with substrate analogs or inhibitors bound. Such an inhibitor was
synthesized by reducing the iminium intermediate formed in the non-enzymatic Pictet-Spengler
reaction between tryptamine and
IJ'MA U27 =,Ilna
secologanin using sodium
cyanoborohydride.28  The crystal
structure of the inhibitor bound
complex shows that the glucose
ring and the terpenoid ring overlay
fcn;rll ~x1ll i r;th the cronlornnin
28  Figure 1.6 - Inhibitor bound structure. The overlay
bound structure (PDB VAQ). shows the tryptamine structure in blue, the
However, the indole ring of the secologanin structure in cyan, and the inhibitor
structure in lavender. Secologanin and tryptamine
inhibitor is twisted almost 900 with are in green, and the inhibitor is in orange.
respect to the native tryptamine structure, and neither of the nucleophilic indole carbons is in the
proper position for cyclization. 28 An overlay of the inhibitor structure with the tryptamine and
secologanin bound structures is shown in Figure 1.6. It appears that the binding pocket of STS
can accept substrate in a variety of different binding modes, not all of which are catalytically
competent. This is an intriguing result, and suggests that further structural characterization with
different inhibitors/substrates bound could provide information pertaining to the scope of
different binding conformations allowed in strictosidine synthase.
1.3.3 Obtaining modified monoterpene indole alkaloids
As previously discussed, there are several different ways to obtain biosynthetically
derived modified natural products. Two of these approaches, precursor directed biosynthesis
(PBD) and mutational biosynthesis (MBS) have yielded promising results for obtaining modified
monoterpene indole alkaloids from C. roseus. Initial efforts towards PDB focused on
determining the substrate scope of STS.34 As the first committed step in MIA biosynthesis, it
was possible that an "unnatural" substrate accepted by this enzyme could be accepted by
downstream biosynthetic enzymes to produce complex modified MIAs. Results from this work
showed that for tryptamine, indole analogs (benzofurans and benzothiophenes) could be
accepted, as could a variety of substitutions on the benzene ring of the indole. For secologanin,
several different esters were accepted, but no other changes were tolerated. Kinetic
characterization showed that the unnatural substrates had a wide range of different affinities,
from equivalent to native substrate to orders of magnitude worse,
Figure 1.7 - Tryptamine
analogs used in PDB. as well as a wide range of activities and catalytic efficiencies.
Accepted:
4 NH2 5 = F
5 , 6 = F These promising results were followed by feeding studies in which
7 N 5 =OH7 H the modified tryptamine substrates were fed to C. roseus cell
cultures. These feeding studies showed that numerous unnatural substrates could be
incorporated into downstream steps, including those shown in Figure 1.7 albeit with varying
degrees of incorporation based on the particular tryptamine derivative used.35
In addition to work towards PDB of modified alkaloids, progress has been made towards
the biosynthesis of modified alkaloids by MBS. Several mutants have been made of C. roseus
crSTS that feature altered or expanded substrate specificity. One such mutant is crSTS D177A
(C. roseus numbering used; subtract six to obtain the R. serpentina numbering), which has been
.... ..1 L. . . . .- . .. -. . .1
foun tO ac;cept a peitiynyl
secologanin derivative with greater
catalytic efficiency than the natural
substrate.36  This mutant was
identified from a rationally generated
library of active site mutants.
Several different ester derivatives Figure 1.8 - Residue D177 was mutated, allowing
STS to accept secologanin ester derivatives. The ester
were tested, but the best results were points out towards D177, while the aldehyde projects
achieved for the pentyny ester. This back into the active site towards E309.
achieved for the pentynyl ester. This
is especially useful as a tag for further derivatization through copper-catalyzed cycloadditions
between azides and alkynes, or "click" chemistry.37 This can be used to add new functionality to
alkaloid products, or to add affinity purification tags to small molecules (i.e. biotin).
Other studies have shown that the substrate specificity of crSTS can be further altered.
Several mutants with expanded substrate scopes were identified from a saturation-mutagenesis
library of active site residues.38 The residues to be mutagenized were selected based on their
position in the crystal structure of rsSTS. Following expression and purification of the mutants,
a high-throughput assay identified variants that accepted unnatural substrates. These include
F232L and V214M (C. roseus numbering), which accept 2'-(R)-tryptophanol and 5-
methyltryptamine respectively. The wild-type enzyme does not accept either of these
compounds. Kinetic analysis of the mutants showed that they showed much lower affinity for
both tryptamine and the modified substrates than the wild type enzyme showed for tryptamine.
Also, the mutants were not as catalytically active as wild type (with either tryptamine or the
unnatural
Figure 1.9 - a) STS active site with mutated residues; b) Unnatural
substrates accepted by STS mutants substrate).38 Despite
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these mutants
orovide the potential
2'-(R)-Tryptophanol
NH2  for incorporating
H even more5-methyltryptamine
B modifications into
the MIA biosynthetic pathway. Transgenic plant cell cultures including these mutants should be
able to produce modified alkaloids.
1.4 Benzylisoquinoline alkaloids
The benzylisoquinoline alkaloids comprise another diverse and medically important class
of alkaloid natural products, a selection of which are shown in Figure 1.10. Benzylisoquinoline
alkaloids (BIAs) are primarily produced by five different plant families, including
Papaveraceae, Fumariaceae, Ranunculaceae, Berberidaceae, and Menispermaceae.39 One of
the most important and most well studied of these is the opium poppy (Papaver somnifernum).
In addition to morphine, a molecule for which the medical and historical importance cannot be
understated, this plant produces the analgesic codeine, the muscle relaxant papaverine, the
antibiotic sanguinarine, and the antineoplastic noscapine. 39 The number of biologically active
molecules isolated from this single species is staggering. Another benzylisoquinoline alkaloid of
c~,,,
note is berberine, a potent antimicrobial compound.40 Outside of the five main plant families,
there are several other species that have been found to produce BIAs in appreciable amounts.
Most interesting among these is Thalictrum flavum,
Figure 1.10 - Medicinally important
common meadow rue, which has been found to benzylisoquinoline alkaloids.
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morphine and berberine, seen in Figure 1.10. Noscapine Papaverine
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1.4.1 Biosynthesis of benzylisoquinoline alkaloids
Elucidating the biosynthesis of BIAs shares the same challenges as studying any other
plant biosynthetic pathway. However, due to the historical importance of morphine and the other
medicinally relevant BIA alkaloids, much is known about these pathways. The first committed
step in BIA biosynthesis is a Pictet-Spengler reaction between dopamine (the aromatic amine)
and 4-hydroxyphenylacetaldehyde (4-HPAA, the aldehyde).42 Both of these precursors are
derived from the amino acid tyrosine by a series of decarboxylation and oxidation reactions.43
This reaction is stereoselective, and is catalyzed by the enzyme norcoclaurine synthase (NCS) to
give the product (S)-norcoclaurine. Following this reaction, a series of methylations and
oxidations occur to give a variety of different intermediate molecules.3 The biosynthetic
pathway of papaverine branches off early in the sequence from the intermediate (S)-coclaurine.
After several more steps, the berberine-type BIAs and morphine-type BIAs diverge from the
intermediate reticuline. Interestingly, berberine synthesis proceeds from the (S)-reticuline
enantiomer, while morphine biosynthesis proceeds from the (R)-reticuline form.3 In the
morphine biosynthetic pathway, two coupling reactions between the two aromatic rings produce
the intermediate thebaine, which is further converted into codeine and morphine. 3
Scheme 1.3 - Early steps of BIA biosynthesis.
NH2  NH NH
HO HO HO
L-Tyrosine HO Norcoclaurine HO H BIAsSynthase
HO HO
HO (S)-Norcoclaurine (S)-Coclaurine
There are several parallels that can be drawn between monoterpene indole alkaloid and
benzylisoquinoline alkaloid biosynthesis. Both biosynthetic pathways begin with a
stereoselective, enzyme catalyzed Pictet-Spengler reaction in the first committed step. In one
step, a highly functionalized molecule is synthesized for transformation into a wide range of
different product structures. Also, both pathways are highly divergent, producing a large number
of compounds with many different structural types. However, while the (S)-norcoclaurine
molecule produced by NCS is quite reactive, featuring two electron rich aromatic rings, there is
no reactive intermediate similar to that produced upon the deglycosylation of strictosidine. The
relationship between these two pathways illustrates both the parallels and the differences among
plant alkaloid natural product biosynthetic pathways.
1.5 Norcoclaurine synthase
1.5.1 Multiple forms and their relation to strictosidine synthase
The structure of the common precursor to benzylisoquinoline biosynthesis was not
identified until recently, hampering the identification of the enzyme catalyzing this
transformation. Norcoclaurine synthase was first isolated from cultures of Eschscholzia
tenuifolia, but its ability to accept incorrect substrates (3,4-dihydroxyphenylacetaldehyde in
addition to 4-HPAA) led to the incorrect assignment of the common precursor.44 Once the
correct precursor molecule of (S)-norcoclaurine was identified in the early 1990s, this mistake
was apparent.42 However, little work was done on NCS throughout this decade. More detailed
studies of this enzyme, including isolation from several plant species, activity assays, and kinetic
characterization, were published in 2001 and 2002. 39,45 The enzyme was initially purified from
Thalictrumflavum, and as such will be referred to as tfNCS. tfNCS is a -25 kDa protein that
feature a 19 amino acid N-terminal signal peptide with no associated metals or cofactors. The
gene has been cloned and the protein has been expressed heterologously in E. coli (truncated to
remove the signal sequence).46 No sequence homology has been detected between tfNCS and
strictosidine synthase (from any species), however tfNCS does have 50-60% homology with
members of class 10 pathogenesis related proteins, which are a class of pollen and food
allergens. 47 The relationship between tfNCS and STS appears to represent an example of
convergent evolution.
In addition to enzymes characterized from T. flavum, enzymes involved in the initial
steps of BIA biosynthesis have been characterized from another plant species, Coptisjaponica.48
In this work, screening of expressed sequence tag (EST) clones in a cell culture line selected for
enhanced BIA production revealed a new form of NCS, bearing no homology to tfNCS or STS.
This new enzyme, termed cjNCS, was isolated from cell cultures, purified to homogeneity
through chromatographic methods, and sequenced. Following sequencing, comparison of the
cjNCS sequence to other Pictet-Spenglerase sequences showed no homology. However, this
enzyme did show homology to 2-oxoglutarate dependant non-heme iron dioxygenases.
Interestingly, assays showed that the enzyme did not require oxygen or 2-oxoglutarate to
function, but assays performed in the presence of the chelator o-phenanthroline suggested that
Fe2+ is required for activity.4 8 These results were rationalized in view of a sequence alignment of
cjNCS with other plant 2-oxoglutarate-dependent non-heme iron enzymes, which showed that
the iron binding residues of cjNCS were conserved, but the 2-oxoglutarate binding region,
conserved in all other enzymes of this class, was not conserved in cjNCS.
Along with cjNCS, another enzyme was identified from C. japonica on the basis of
sequence homology with tfNCS and class 10 pathogenesis related proteins.48 This enzyme,
called cjPRIOA, was also demonstrated to have Pictet-Spenglerase activity, although it was not
up-regulated in the BIA producing cell cultures. cjPRIOA was shown to have an expanded
substrate scope compared to cjNCS, accepting 4-hydroxyphenylpyruvate in addition to the native
substrate 4-HPAA.4 8 Also, the product produced by cjPRIOA had the same mass as that
produced by cjNCS, but a different elution time by LC/MS. Finally, cjPRIOA was found to have
an N-terminal signal sequence like tfNCS, while cjNCS showed no such signal sequence. There
are still several unresolved issues raised by this work, but further studies of a Pictet-Spenglerase
like cjNCS with a potentially novel mechanism may lead to a broader understanding of the
requirements for enzyme-catalyzed stereoselective Pictet-Spengler reactions.
1.5.2 Reaction mechanism of T. flavum norcoclaurine synthase
Recently, a detailed mechanistic study has illuminated the mechanism of the Pictet-
Spengler reaction catalyzed by tfNCS.49 This work used alternative substrates and kinetic
isotope effects to differentiate between two possible reaction mechanisms. Also, analysis of
substituent effects helped to support the mechanistic conclusions. While this proposed
mechanism is similar to that proposed for STS, the hydroxyl groups present on the aromatic ring
of dopamine allow for the reaction intermediate to be charge neutral. Also similar to STS, the
deprotonation of the reaction intermediate appears to be the rate-limiting step. These seem to be
common features for enzyme catalyzed Pictet-Spengler reactions. Also of note, this study
determined that dopamine exhibited positive cooperative binding, with a Hill coefficient of 1.8.
This supports the previous evidence that tfNCS functions as a dimer in solution.45
1.5.3 NMR based homology model of T. flavum norcoclaurine synthase
Recently, a report
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Scheme 1.4 - Proposed reaction mechanism of NCS. acids were removed trom the N-
terminus. Using NMR
spectroscopy, a semi-experimental homology model was constructed based on homology with
the major birch pollen allergen Betvl. Betvl was selected based on the significant homology
between this protein and tfNCS, and the availability of an X-ray crystal strucutre. 51 CD
spectroscopy verified that Betvl and tfNCS had similar secondary structure and thermal stability
properties, supporting the choice of this protein as a starting point for homology modeling.
Following the expression and purification of isotopically labeled protein, NMR
measurements yielded signals for 86% of the tfNCS sequence. In addition to native
measurements, the protein was also studied in the presence of substrates to attempt to localize the
binding pocket. To investigate 4-HPAA binding, several different analogs were employed
including methyl(4-hydroxyphenyl)acetate and 2-(4-hydroxyphenyl)ethanol. Upon inclusion of
these analogs, widespread changes in chemical shifts were observed, suggesting that 4-HPAA
binding induces a significant structural rearrangement. For dopamine binding, a much smaller
set of residues exhibited chemical shift changes. These included residues 69-72 and 150-155.
Within these regions, several hydrophobic residues may be involved in interactions with the
aromatic ring of dopamine, including F71 and M155. Near the putative dopamine binding site,
there is one acidic residue, E75, that may play the same role in tfNCS as E309 plays in STS,
namely that of a general acid/base catalyst. This seems plausible in light of the mechanistic
studies showing similar mechanisms for these two enzyme catalyzed reactions.
While many new insights can be drawn from this structural characterization, there are
still numerous unanswered questions. For instance, what are the specific interactions involved in
substrate binding? What are the structural rearrangements caused by 4-HPAA binding? It has
been shown that the two substrates show ordered binding, with 4-HPAA binding first.45 How do
the structural changes affect dopamine binding and catalysis? Is E75 really poised to be a
catalytic residue, or is it just in the vicinity of the binding pocket without playing a role in the
reaction? Further structural characterization would aid in answering these questions, in addition
to suggesting residues for mutation for enzyme engineering.
1.6 Summary and goals
Natural products are a rich source of bioactive molecules used for treating a wide range
of human diseases. Alkaloids compose one of the largest and most structurally diverse classes of
natural products. Two sub-classes of plant-derived alkaloids, the terpene indole alkaloids and the
benzylisoquinoline alkaloids, have provided several well-known therapeutics that are widely
used today. The structural diversity and complexity of these compounds makes chemical
synthesis difficult and expensive. As such, the synthesis of analogs that may have modified or
improved biological activity and the eventual large-scale production of these potentially
improved compounds present a significant challenge.
An attractive solution is the production of modified alkaloids by utilizing mutational
biosynthesis, or mutasynthesis. This methodology entails altering the enzymes in a biosynthetic
pathway, feeding a reengineered producing organism a modified substrate, and isolating the
"unnatural" product. Mutational biosynthesis requires a detailed understanding of the enzymes
that function in alkaloid biosynthetic pathways, and an understanding of how mutations to these
enzymes affect their function and substrate specificity. Structural characterization of enzymes
involved in alkaloid biosynthesis by x-ray crystallography is critical for this task, as is structural
characterization of mutants with expanded or altered substrate specificities.
The first committed step in terpene indole alkaloid biosynthesis is catalyzed by
strictosidine synthase, an enzyme that catalyzes a Pictet-Spengler reaction coupling tryptamine
and secologanin to form strictosidine. Several STS mutants have been identified with expanded
substrate specificity, accepting tryptamine analogs that are not turned over by the wild type
enzyme. One STS mutant has been found with altered substrate specificity, accepting a
secologanin analog preferentially over the natural secologanin substrate. Understanding how
these mutations confer different binding activities at atomic resolution will allow for catalysis of
substrate analogs by maximizing productive binding modes through rational mutagenesis.
Analogous to terpene indole alkaloid biosynthesis, the first step in benzylisoquinoline
alkaloid biosynthesis is the Pictet-Spengler coupling of dopamine and 4-HPAA to form
norcoclaurine catalyzed by norcoclaurine synthase. Interestingly, there is no sequence homology
between STS and NCS, even though they catalyze the same reaction. Even more interesting is
the fact that the two enzymes (cjNCS and tfNCS) known to carry out norcoclaurine synthesis
share no sequence homology. One of these enzymes (cjNCS) shows similarity to 2-oxoglutarate-
dependant oxygenases and dependence on ferrous iron, but not 2-oxoglutarate or oxygen.
Structural characterization of cjNCS, and further structural characterization of tfNCS, should
provide insight into the mechanism, as well as suggest residues for mutation to change the
substrate specificity of this enzyme and allow mutational biosynthesis of benzylisoquinoline
alkaloids.
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2. Strictosidine Synthase Crystallization Studies
2.1 C. roseus strictosidine synthase
Strictosidine synthase (STS) is the first committed enzymatic step towards making the
wide variety of terpene indole alkaloid natural products.' As the first committed step, it serves as
a gateway to the monoterpene indole alkaloids; modified starting materials for use in precursor
directed biosynthesis or mutational biosynthesis must pass through STS before they can proceed
to more complex alkaloid structures. Efforts towards precursor directed biosynthesis have
shown that STS has some degree of promiscuity, however the scope of substrate analogs
accepted will ultimately limit the modified alkaloids that can be produced.2'3 Mutational
biosynthesis provides a way around this limitation, providing the potential for an even broader
spectrum of modified natural products.4
To identify mutants of STS with potentially expanded substrate specificity, a saturation
mutagenesis library of relevant residues (as identified in the crystal structure of R. serpentina
STS) was constructed.5 Following expression and assay, several mutants were found which could
accept substrate analogs unaccepted by native STS. Most notable among these analogs are
V214M, F232L, and D177A.5' 6 Structural characterization of these analogs will provide insight
into why these particular mutations accept these analogs, as well as provide rationale for further
mutagenesis studies. Additionally, crystallography of the native enzyme with substrate analog
inhibitors will allow us to probe the active site further and elucidate productive and unproductive
binding conformations.
2.1.1 Kinetic characterization of wild-type STS
Previous experience in the O'Connor lab has shown that the activity of crSTS is highly
dependent on the specific construct. For example, the native protein has an N-terminal signal
sequence that functions in cellular localization in the producing organisms. To obtain active
protein from E. coli, the protein must be expressed as a truncated form without this leader
peptide sequence. Also, several different constructs featuring a maltose binding protein (MBP)
affinity purification tag at the N-terminus showed strongly reduced activity. For the purposes of
crystallography, a much smaller affinity tag was desired. Because of the reduction of activity
associated with substitution at the N-terminus, a C-terminal His-tag was selected. Since this was
the first C-terminal His-tagged construct to be expressed and purified, its activity was verified
with a brief kinetic characterization. Assays were only performed once so an analysis of error is
not possible, however the results are consistent with previous kinetic characterizations of
crSTS.7 ,8
crSTS was cloned, expressed, and purified as detailed in the Materials and Methods
section. To determine the steady-state kinetic parameters for crSTS, assays were run in which
the concentration of tryptamine was varied under pseudo-first order conditions ([secologanin] >>
Km,sec). Previous kinetic characterization of crSTS showed that the Km,trp to be between 2-10
tM. In light of this, the following tryptamine concentrations were used: 1, 2.5, 5, 10, 50 ýtM.
Data were analyzed using the following formula:
([(Astrict/ANAA)*ANAA(Avg.)]/Estrict)/Time = (v0o pM/min)/[crSTS] = kcat (min- )
Astrict = integrated area under the curve for strictosidine
ANAA = integrated area under the curve for NAA
ANAA(Avg.) = average area under the curve for all NAA measurements
Estrict = extinction coefficient for strictosidine at 280 nm = 12000 jtM-lcm -
vo = initial rate
Time = time of quench in minutes
Plotting vo vs. [tryptamine] produced a plot characteristic of Michaelis-Menton kinetics.
Non-linear regression was performed using the Origin software package (version 7.0) to give
kinetic parameters.
Kinetic characterization was performed twice using two different preparations of crSTS.
The first was done using partially purified (Ni-NTA) crSTS, the second was done using
electrophoretically homogenous crSTS following size exclusion chromatography. The non-
linear regression plots for these two trials can be seen in Figure 2.1. The different kinetic
parameters can be seen in Table 2.1.
Figure 2.1 - Kinetic characterization of crSTS. The left plot shows Ni-NTA purified
kinetics, the right plot shows pure kinetics.
Table 2.1 - Kinetic parameters for different preparations of crSTS
Ni-NTA purified SEC purified
kcat (min -') 27.8 142.5
Kin, tryptamine M) 15.5 7.7
kcat/Km (min - g M-') 1.8 18.5
As expected, the kinetic parameters were shown to improve upon further purification of
crSTS. Data analysis for the fully purified crSTS was complicated by the fact that in some
HPLC traces there was an unidentified peak that partially obscured the NAA standard. This peak
did not show time dependence, nor did it seem to be related to the concentration of any of the
reaction components. In some traces, the peak was distinct enough to be integrated separately,
however in others it overlapped with the NAA peak to such a degree that independent integration
was impossible. It is hypothesized that this peak could be due to polymerization of un-reacted
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secologanin, but no characterization was done to investigate this. Because the kinetic parameters
for fully purified crSTS were similar to those of the native enzyme and the main aim of this
project is structural and not kinetic, these results were deemed satisfactory.
2.2 Crystallization experiments with C. roseus STS mutants
The crSTS mutants V214M, F226L, and D177A were obtained by site-directed
mutagenesis performed on the gene in the pET-28a expression vector. Purification of the
mutants proceeded as with the native protein. Following MonoQ chromatography, relevant
fractions were collected and analyzed by SDS-PAGE. Even though the protein still contained
some contamination, as shown in Figure 2.2, it was decided to attempt crystallization with the
current preparation rather than perform further chromatography and potentially reduce the ability
of STS to crystallize. Based on the success of subsequent crystallization screens, these mutants
should be further purified before crystallization is attempted again. Also, future purifications
should not include glycerol unless long-term freezer storage is anticipated.
STS D177A STS F226L
Figure 2.2 - SDS PAGE of crSTS mutants after Mono Q chromatography
Fractions from MonoQ chromatography were pooled and concentrated using an Amicon
Ultra Centrifugal Filter device. crSTS F226L was concentrated to 15 mg/mL (from - 10 g cell
pellet). Repeating the purification using -30 g cells (wet weight) afforded enough protein to set
up screens at 7.5 mg/mL. Using crSTS F226L and D177A, initial crystallization screens were
begun.
2.2.1 Sparse matrix screening with D177A and F226L
All crystallization screens were set up in 24 well plates using siliconized glass cover
slides and sealed with vacuum grease. For each well, 500 gIL of the pre-mixed condition was
used as mother liquor. To construct the hanging drop, 1.5 giL of protein was mixed with 1.5 gtL
of mother liquor on the glass cover slide and then inverted and sealed on top of the well.
Equilibration was allowed to occur, and wells were observed after 2, 4, and 6 days for scoring.
Wells were observed at intermittent time periods after the six days, but were not officially
scored.
The Hampton Index Screen (HR2-144) was used for crSTS D177A. Numerous drops
showed a light precipitate, and many others stayed clear. No hits appeared promising for
optimization. Due to the faintness of even the amorphous precipitates, it is thought that the
concentration was too low. Further work would include attempting these screens again at a
higher concentration.
For crSTS F226L, the Hampton Index Screen (HR2-144) and Hampton Crystal Screen
(HR2-110) were initially used at room temperature. Several wells in the index screen which
included polyethylene glycol showed granular precipitation or microcrystals, so the PEG/Ion
screen (HR2-126) was investigated at room temperature and 4 'C and the PEG/Ion 2 screen
(HR2 - 098) was investigated at room temperature. Numerous wells in both screens showed
heavy amorphous precipitation, although some drops remained clear for the length of the
observation period. There were few granular precipitates, other that those in the PEG containing
conditions. However it seemed that the protein was well behaved and might eventually be
optimized to produce crystals.
A potential hit was
Figure 2.3 - Pictures of crystals in PEG/Ion condition 1
before and after "Izit" staining. No staining is observed, seen in PEG/Ion condition
1 after 5 days at both room
temperature and 4 "C.
Pictures of these crystals
are shown in Figure 2.3.
This condition contains 0.2
M NaF, 20% w/v PEG 3350; because of the NaF it is especially prone to forming salt crystals.
However, several crystals were picked and analyzed following cryo-protection in 0.2 M NaF,
20% w/v PEG 3350, 20% ethylene glycol. One image was collected over 15 minutes with a 10
oscillation and a detector distance of 300 cm starting at 900. This was repeated with a 20 minute
exposure starting at 1800. The maximum resolution was
to 3.3 A, and very few spots were visible. A
representative image may be seen in Figure 2.4. Based
on the x-ray diffraction, it was concluded that these
crystals were salt.
Despite the x-ray results, the crystals were
investigated further. Addition of 1 gL of mother liquor
resulted in the formation of new crystals, strongly
Figure 2.4 - X-ray diftion fraction of
supporting the case for salt. The crystals showed no PEG/Ion Condition 1 crystals.
staining with Izit dye and no protein was visible on SDS-PAGE, indicating that these were salt
crystals.
2.2.2 Optimizing crystallization of F226L
At this point, first index screens set up were re-examined. Numerous small spherules
were observed in condition 35. This condition included 1.0 M ammonium sulfate, 0.1 M HEPES
pH = 7.0, 0.5% w/v PEG 8000. These spherules were too small to screen for diffraction, but
they were well stained by Izit dye (Figure 2.5). To optimize the crystallization for speed (1-2
weeks) and quality (larger, better morphology), several new screens were performed varying
different components of the mixture. The components were pre-mixed in 1 mL Eppendorf tubes
by vortexing. As before, 500 gL was used as mother liquor and the drop size was 1.5 IL.
Table 2.2 - Optimizing crystallization of crSTS F226L by grid screening
Screen # Constant Varying Results
Screen 1 0.1 M HEPES pH = 7.0 PEG 8K-0.5-20% Potential hits within 5 days at
Room Temperature (NH4)2SO 4 - 0.5-2 M 5% and 10% PEG.
Screen 2 0.1 M HEPES pH = 7.0 PEG 8K - 0.5 - 16% There is a problem with
Room Temperature (NH4)2SO 4 - 0.5-2 M miscibility above 1 M
(NH4)2SO 4 and 2% PEG. The
hits from screen one were
simply immiscible droplets.
Screen 3 0.1 M HEPES pH = 7.0 PEG 8K- 0-1.5% Nothing seen within I week.
Room Temperature (NH4)2SO 4 -0-1.25 M Eventually, small spherules
developed in some wells (over
-4 wks).
Screen 4 0.1 M HEPES pH = 7.0 PEG conc. - 0.5-20% After one week, a potential rod
0.5 M (NH4)2SO 4  PEG MW - 3350, 6K, was seen in 5% PEG 20K, but it
Room Temperature 8K, 20K did not stain, was too thin for
diffraction, and was not
reproducible.
Screen 5 0.1 M HEPES pH = 7.0 PEG 20K- 0.5-10% No hits seen in an appreciable
Room Temperature (NH4)2SO 4 - 0.4-0.6 time period (after 2 weeks)
M
Future work towards crystallizing crSTS F226L would include repeating the initial
screens at lower protein concentrations (i.e. 10 mg/mL). Also, glycerol should not be included in
L1IC y; YtlLULU1l UUIL•I. rlIaldly,
different protein buffers could be
investigated to see which would
produce the least amount of
precipitation.
Figure 2.5 - Izit staining of crSTS F226L Index 35
2.3 Crystallization experiments with wild-type C. roseus STS
2.3.1 Sparse matrix screening for initial conditions
It is essential to verify the activity of a protein before attempting crystallization screens.
This ensures that any structural information obtained will be of a relevant form of the protein. A
detailed kinetic characterization was not necessary; a qualitative assay was all that was required.
To assay crSTS, a previously described colorimetric assay was performed.5,9' 10 The reaction
mixture for this assay includes crSTS, both tryptamine and secologanin substrates, and
strictosidine glucosidase (SG), the next step in the biosynthetic pathway of the terpene indole
alkaloids. Deglycosylation of the strictosidine produced by STS yields a reactive intermediate
that undergoes a series of rearrangements to eventually yield a yellow and insoluble precipitate.
The yellow chromophore forms only in the presence of active STS when the reaction is
incubated at 30 oC. Compared to a no enzyme control, crSTS showed a strong yellow color and
substantial precipitation after a 10 minute incubation at 30 oC.
After verifying the activity, electrophoretically homogenous crSTS was used for initial
sparse matrix screens. The Hampton Index Screen (HR2-144) was used with the following
protein solutions- 10 mg/mL crSTS, 10 mg/mL crSTS + 1 mM tryptamine, 5 mg/mL crSTS, 5
I
i
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mg/mL crSTS + 1 mM tryptamine. For trials including tryptamine, the protein and tryptamine
were pre-incubated for several hours before trays were set up. For screening, the hanging drop
vapor diffusion method was used. Briefly,
Figure 2.6 - Pure crSTS after SE200
chromatography this method features a drop of protein +
precipitant solution suspended hanging over a
well of mother liquor (usually the precipitant
solution). The drop is placed on a siliconized
glass cover slip, which is then inverted over
the well. The edges are sealed with vacuum
grease to create a closed environment. As
water vapor diffuses from the drop into the mother liquor, it slowly concentrates. This increases
the concentration of protein and precipitant, ideally resulting in gradual crystal nucleation and
growth. All screens were performed at room temperature with 500 jiL wells and 3 jiL drops (1.5
tL each protein and mother liquor). Trays were observed 2, 4, and 7 days after being set up for
scoring.
In general, this protein preparation gave much improved results compared to previous
trials with crSTS F226L. While some wells showed heavy amorphous precipitation, the other
wells showed a range of results. A large number of wells showed granular precipitation, and
many showed small microcrystals. While none of the wells showed crystals in 2 weeks, there
seemed to be potential for optimizing crystal formation from one of the many drops with
microcrystals. However, due to the large number of wells with microcrystals, it was reasoned
that trying to crystallize the protein at 4 oC might promote formation of crystals from one of
these drops. Before beginning grid screening around an arbitrarily chosen microcrystalline
option, the Index screen was investigated at 4 oC.
Before setting up the trays for the reduced temperature Index screen, all buffers, trays,
pipette tips, and cover slips were cooled in the cold room for -3 hours. crSTS at 5 mg/mL was
used to set up the trays. The previous trials had shown that 5 mg/mL protein worked as well as
10 mg/mL protein while giving fewer wells with heavy precipitation. Even though previous
trials showed no improvement of crystal morphology/size with tryptamine, it was used as in co-
crystallization in the hopes that it would give better crystals at 4 oC. After the screens were set
up, they were observed at 1, 4, and 6 days. While waiting for results from these screens,
Hampton Crystal Screen 1 (HR2-110) was set up at room temperature at 5 mg/mL with and
without tryptamine.
On the fourth day, small spherulites were observed in Figure 2.7 - Initial Hit for
SO" u . crSTS (Index #90)
Inuex screen conuituon 90 at 4' C (sho "wn in g 2 /,.). is
conditions contained 0.2 M Sodium formate and 20% (w/v)
PEG 3350. These crystals were seen in drops with and
without tryptamine, however the tryptamine drop showed
heavy precipitation on the sixth day while the drop without
tryptamine stayed clear (except for the crystals, of course).
Since this was the best hit so far, it was selected for
optimization by nrid screenine.,,
2.3.2 Optimizing crystallization of wild-type STS
Initial grid screening focused on changing the concentration of sodium formate, the
concentration of PEG 3350, and the molecular weight of the polyethylene glycol (3350, 6000,
8000, 20000). All grid screens were set up at 4 oC in the same manner as the reduced
temperature sparse matrix screens. As before, the mother liquor volume was 500 1IL and the
drop volume was 3 [tL (1.5 giL mother liquor, 1.5 [tL 5 mg/mL crSTS in 10 mM Tris-HCl pH =
7.5). Also as before, 24 well plates were used and the wells were sealed with siliconized glass
cover slips. An example of one of these sparse matrix screens is shown in Table 2.4.
Table 2.3 - Sparse matrix screening of crSTS.
Screen Concentration Tryptamine Temperature Results
(mg/mL) (+/-)
Index 10 - r.t. Range of results, from heavy ppt to
microcrystals.
Index 10 + r.t. Range of results, from heavy ppt to
microcrystals; a lot of drops with skin.
Index 5 - r.t. Better behaved than more
concentrated screen, fewer wells with
heavy ppt, more granular ppt and
microcrystals.
Index 5 r.t. Same as without tryptamine, but with
more drops with skin.
Index 5 - 4 oC Range of results
Hits: Condition #90 (0.2 M HCOONa,
20% w/v PEG 3350)
Index 5 + 4 oC Range of results
Hits: Condition #90 (0.2 M HCOONa,
20% w/v PEG 3350); proceeding to
heavy precipitate in several days.
Crystal 5 - r.t. Range of results, no utilizable hits.
Screen
Crystal 5 + r.t. Range of results, no utilizable hits.
Screen
Table 2.4 - Typical grid screen of crSTS
0.1 M HCOONa 0.1 M HCOONa 0.1 M HCOONa 0.1 M HCOONa 0.1 M HCOONa 0.1 M HCOONa
14% PEG3350 16% PEG3350 18% PEG3350 20% PEG3350 22% PEG3350 24% PEG3350
0.2 M HCOONa 0.2 M HCOONa 0.2 M HCOONa 0.2 M HCOONa 0.2 M HCOONa 0.2 M HCOONa
14% PEG3350 16% PEG3350 18% PEG3350 20% PEG3350 22% PEG3350 24% PEG3350
0.3 M HCOONa 0.3 M HCOONa 0.3 M HCOONa 0.3 M HCOONa 0.3 M HCOONa 0.3 M HCOONa
14% PEG3350 16% PEG3350 18% PEG3350 20% PEG3350 22% PEG3350 24% PEG3350
0.4 M HCOONa 0.4 M HCOONa 0.4 M HCOONa 0.4 M HCOONa 0.4 M HCOONa 0.4 M HCOONa
14% PEG3350 16% PEG3350 18% PEG3350 20% PEG3350 22% PEG3350 24% PEG3350
As a result of multiple grid screens, it was discovered that changing the concentration of
sodium formate did not affect crystal formation, but changing the concentration of PEG 3350
had a large effect. Crystals that formed from 12%-16% PEG 3350 were larger than the initial
crystals, although they did not have markedly better morphology. Some of these larger crystals
were sacrificed to characterize the nature
Figure 2.8 - crSTS crystal characterization. a)
of the crystals. Some were stained with Izit staining; b) SDS-PAGE analysis
Izit dye, a proprietary dye sold by
Hampton Research. To stain, 0.5 pL of
Izit dye was added to the 3 gL drop.
Protein crystals should stain blue because
the dye can diffuse into the crystal due to the larger spaces left between lattice contacts. Salt
crystals should not stain because the spaces between lattice contacts should be too small to allow
dye molecules to diffuse in. These crystals stained well and analysis by SDS-PAGE revealed a
single protein band at the appropriate apparent molecular weight. At this point, it was concluded
that the crystals were protein and suitable for diffraction screening.
Crystals of crSTS were screened for diffraction at the Drennan lab X-ray source under
cryogenic conditions. The crystals to be screened were looped and frozen directly in the 100 K
cryostream. Initially, data was collected in a one degree oscillation (Aý = 1) over fifteen minutes
with the detector set to 300 mm. The first image collected was from protein crystallized in 0.2 M
HCOONa, 16% PEG3350. It seemed to show irregular low resolution spots at very low
intensity. An image collected on the same crystal at 900 from the first image showed no
difference. After this, the detector was moved in to 250 mm and the exposure time was
increased to 20 minutes (still for Aý = 1). This gave no improvement over previous images
taken.
After the poor results with the first crystal, several other crystals were screened for
diffraction. For this second batch, cryo-protection was used to preclude lack of diffraction due to
ice formation. Cryo-protection involved a five minute soak in the mother liquor solution with
20% glycerol added. After cryo-protection, the crystals were frozen in the cryo-stream as before.
All crystals screened with cryo-protection gave the same general results as those screened
without cryo-protection. Some images were taken using a A4 = 5 to rule out salt crystals; these
image showed no diffraction/weak diffraction and were clearly not salt patterns. Even increasing
the exposure time to 45 minutes did not produce clear, unambiguous diffraction. The best results
were obtained from a single crystal in a single orientation that gave weak, smeary spots at low
(-10-15 A) resolution. It was concluded that these crystals were too poor to produce good
diffraction; further optimization of the crystallization conditions was performed.
To obtain better crystals with improved morphology and, most importantly, better
diffraction, additive and detergent screens were investigated. These screens are similar to sparse
matrix screens, containing an array of different additives including salts, sugars, polymers,
detergents, etc. Each screen contains 24 unique additives; detergent screen 1 and additive
screens 1-3 were initially tried. For these screens, the initial conditions from Index Screen #90
were used (0.2 M HCOONa, 20% PEG3350) for the mother liquor. Trays were set up as
described above with the only difference being the composition of the hanging drop. For the
additive/detergent screens, the hanging drop included 1.5 gL mother liquor, 0.3 gL additive, and
1.2 gL 6.25 mg/mL crSTS. The concentration of the protein was increased slightly to
compensate for the added dilution and keep the final concentration of crSTS in the drop at 2.5
mg/mL. The hanging drop components were added in the order listed above (mother liquor
followed by additive followed by protein) to ensure that the additive was fully ejected from the
pipette tip into the drop. The screens were incubated at 4 'C and observed at 2, 4, and 6 days
after being set up. They were scored on a simple scale of +, -, or 0 (+ = improved morphology, -
= worse morphology, 0 = no visible change in morphology).
After 2 days, a greatly increased morphology was seen in additive screen 1, condition 14.
This condition contains 30 % (v/v) (+/-)-2-methyl-2,4-pentandiol (MPD) at a final concentration
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crystal morphology changed from the
rough, irregular spheres seen in
previously optimized conditions to thin,
rectangular plates. These plates were sometimes found in stacked clusters and sometimes as
single plates. A few of the single plates appeared to be slightly thicker than others. Grid
screening to further optimize the conditions revealed that better morphology (i.e. larger plates,
more single plates) was obtained with higher MPD concentrations and lower PEG
concentrations. Optimal crystals were obtained from 9%-14% MPD and 10%-16% PEG3350.
During this optimization, an inhibitor of crSTS was used in co-crystallization
experiments to aid in crystal formation/growth. Also, one of the aims of this project is the use of
inhibitors to probe the enzyme active site, so using an inhibitor in co-crystallization would be a
step towards this goal. Tryptamine and secologanin were linked through an amide linkage to
form the inhibitor (synthesized by W. Runguphan, unpublished results). The inhibitor has an
IC50 of 1 jtM; this was converted using the Cheng-Prusoff Equation to give a to a Ki value of
-0.3 tM. Because of this, the inhibitor was used at a 10 giM concentration in the hanging drop.
Crystallization was tested over a range of PEG3350 concentrations (6%-16%) while keeping
MPD concentration constant at 9%. Drops without the inhibitor included were set up as a
control. After several days, the crystals in the inhibitor drops showed no improvement relative to
the control. The inhibitor concentration was then varied between 5 tM and 10 gM (still vary
PEG3350 in the same ranges and keeping MPD constant). Again, even after several days there
was no improvement relative to the control drops. At this point, co-crystallization experiments
were stopped. To obtain structures with inhibitors bound, further co-crystallization or soaking
experiments will be necessary.
Since many of the
crystals in the optimized
conditions were still very thin,
macroseeding was used to obtain
thicker, more three-dimensional crystals. Macroseeding is a technique in which a pre-formed
crystal is used as a seed for more crystal growth. The crystal is first "etched" by transferring it to
a solution with a slightly lower precipitant concentration than that used to form the crystal. This
allows the edges of the crystal to dissolve slightly. After etching, the crystal is transferred to a
drop with fresh protein solution in it at a slightly lower concentration than that used to form the
seed. Upon equilibration, the protein in solution should grow onto the etched edges of the
macroseed instead of forming new crystals. It is essential that the protein in the new drop be at a
lower concentration. If not, microseeds transferred along with the macroseed can produce
multiple nucleation sites and consume most of the protein in the drop in forming small and
useless crystals. A selection of thicker crystals obtained using this method are pictured in Figure
2.10.
2.3.3 Screening crystals for diffraction
Optimized crystals from macroseeding were obtained approximately two weeks before a
scheduled trip to the synchrotron at the Argonne National Laboratories Advanced Photon Source
(APS). High resolution and high quality data sets are usually collected at synchrotron radiation
sources. Synchrotron sources can produce much more intense and much more focused X-rays
than those which can be produced at our home X-ray source. Several crystals were examined on
a home X-ray source to judge which crystals to send to the synchrotron.
For this round of screening, all crystals were cryo-protected in mother liquor plus 20%
glycerol for five minutes. Following cryo-protection, crystals were looped and flash frozen in
liquid nitrogen before being placed in the 100 K cryo-stream. Large, single crystals were
initially selected for screening and were looped using 0.3-0.4 mm microloops. The starting
exposure time was 10 minutes, the detector distance was set at 300 mm, and the oscillation was
one degree. The first diffraction image showed clearly that this was protein, as did an image
taken at 90 o from the first. Several different crystals were screened in the time available; the
results for the different crystals are shown in Table 2.5.
The data collected during screening of
these crystals was encouraging for several
reasons. First of all, it showed that the optimized
crystals were clearly protein and diffracted to
moderate resolution (3.0-4.5 A). Since they
diffracted to this resolution at our home source, it
was a good assumption that they would diffract to
higher resolution with more intense X-rays at a
synchrotron radiation source. Secondly, it seemed
Figure 2.11 - Diffraction results for
crSTS-5
that a range of different crystals gave good diffraction, and that those sent to the synchrotron
would give similar diffraction. However, the results of screening were not entirely satisfactory.
The appearance of split spots and potential multiple lattices in some of the crystals was troubling,
Table 2.5 - Screening for diffraction before the synchrotron
Crystal Results
crSTS-1 Showed clear protein diffraction to -3.6 A. The spots were strong for the home
source, but they were split. There was a crack in the crystal when it was frozen
which could be contributing to splitting. This crystal was thawed and a single
fragment was broken off.
crSTS-2 Showed clear diffraction to -4.5 A, but the spots were weaker than those for crSTS-
1. The spots appeared highly elliptical, so this crystal was annealed by blocking the
cryo-stream for 10 seconds and re-screened.
crSTS-3 Showed diffraction to -4.5 A with decent looking spot morphology (most appeared
circular).
crSTS-4 Showed diffraction to -3.3 A and had a set of good looking spots. However, some
of the other spots appeared to be split, and there was a good deal of streaking. This
crystal was probably not single.
crSTS-5 Showed diffraction to -4.0 A with decent looking spot morphology. This crystal
gave the best results of any one screened, shown in Figure 2.11.
crSTS-6 This crystal showed poor diffraction and was discarded.
crSTS-1 Following thawing and re-freezing of the chipped off fragment, very poor quality
Fragment and streaky spots were seen. The fragment was discarded.
crSTS-2 Annealing seemed to produce more spots than seen before, but they were streaky.
Annealed Also, the quality of the previously observed reflections decreased after the
annealing procedure. This crystal was also discarded.
raising potential issues with later data processing. Also, the inability to index the crystal based
on the diffraction data collected at home was less than optimal. Nonetheless, several crystals
were sent to the synchrotron for data collection (crSTS-3, crSTS-4, and crSTS-5).
2.4 Data processing with C. roseus STS
Data from crSTS crystals was collected at the Argonne National Laboratories APS. Data
were collected on two different crystals on two different beamlines. For crSTS-3, data was
collected on beamline 24-ID-C, a conventional beamline dedicated to macromolecular
crystallography. For cr-STS-5, data was collected on beamline 24-ID-E, a micro-focused
beamline. The x-ray beam on this beamline can be tuned to a variety of different diameters
between 5-100 Jtm. It is very tightly focused and very intense (more so than other synchrotron
beams). Due to the intensity, crystal decay is a substantial problem. However, the small
diameter of the beam allows for the crystal to be translated once decay begins to reduce data
quality.
Because the space group was not known beforehand, 3600 of data was collected for
crSTS-3. Since crSTS-3 was shot on a regular beamline, the 3600 was collected in a single spot.
A set of the frames, from -20o-650 look suitable for analysis; unfortunately, data outside of these
regions is not usable. Before 20', the diffraction is very weak and much fewer spots are visible.
Above 650, the data quality deteriorates rapidly. This is illustrated in Figure 2.12, with 4 = 450
on the left and 4 = 900 on the right. The figure shows the zoom view of the two images as
displayed in the program Xdisp. The spots become very streaky, looking more like smears than
actual spots. This problem continues through most of the rest of the data set. Due to the fact that
so little of the data looked useful, it was reasoned that this data set would not provide enough
information to solve the structure. Even if it did, the completeness would be so low as the render
the structure highly suspect. For this reason, no further work was done with the crSTS-3 data set
and efforts were concentrated on crSTS-5.
Figure 2.12 - Decay in data quality of crystal crSTS-3.
= 450 4 = 90"
The data set for crSTS-5 was collected on the micro-focused beamline. Because of the
intensity of the beam, data was collected in six different wedges.
Table 2.6 - Data collection for crSTS-5
Wedge # Comments
Covered
1 0"-31" Initial frames look high quality, but data deteriorates towards the end
of the wedge. Lunes are clearly visible, but stray spots appear in some
frames. Spots morphology is good for some spots, less so for others.
2 27"-590 Initial frames look good, but data deteriorates rapidly towards the end
of the wedge. Lunes are clearly visible, but stray spots appear. Spot
morphology is initially good, but becomes worse later in the wedge.
3 54o-90" This is the best looking wedge. Diffraction is strongest here, and the
spots look the best. Also, deterioration of data quality does not look
as bad.
4 85"-1090 This wedge looked similar to wedge 1. Data seems to decay more
rapidly, which is why fewer frames were collected in this wedge.
5 950-1100 Ice rings are visible in this wedge, which is why fewer degrees were
collected here. Spot morphology is poor.
6 120"-242" Initial frames show very few spots. Lunes are not visible, and
diffraction is weak compared to previous wedges. However, later in
the wedge (after -20 frames) the diffraction begins to look better, with
stronger spots, clear lunes, and decent spot morphology. This
deteriorates quickly, with the spots becoming increasingly streaky.
I
After each wedge was collected, the beam was translated down the length of the crystal.
The data for each of the
Bwedges is summarized in
Table 2.6.
In the initial frames
of a wedge, the diffraction
went past 1.9 A, but in later
frames, the decay reduced
Figure 2.13 - Improved diffraction on the micro-focused beam.
the resolution to less than a) Home diffraction; b) Synchrotron diffraction.
2.6 A. For indexing and integration, the data cut-off was set to 2.5 A; for scaling the data was
cut off at 3.0 A. While the data did not look optimal, it was decided to attempt to process these
data. From this point onward, discussion of data processing will refer only to the crSTS-5 data
set collected on the 24-ID-E micro-focused beamline.
2.4.1 Indexing with Denzo
The first step in processing data for any crystal is indexing. Indexing provides
information regarding the space group and unit cell dimensions; this information is used as a
guide when integrating reflection intensities and scaling data sets together. Knowing the space
group is essential because it gives the reflections that are symmetry related. These reflections
can be compared to judge the quality of the data set and the progress of data processing. Also,
knowing how many of the reflections are symmetry related allows you to compute the
completeness of your data set. If there are more symmetry related reflections, a data set with
fewer reflections may still have a large degree of completeness and redundancy.
Using the data from the single frames, indexing was done using the program Denzo (part
of the HKL2000 suite of programs). To index, the program selects a subset of reflections to use
in its calculations. It then attempts to fit this selection of spots to the results that would be
obtained from each of the potential space groups. For each potential space group, the program
computes possible unit cell dimensions that would be consistent with the set of spots used in the
calculation. In addition to giving unit cell dimensions, the distortion index is also calculated.
The distortion index is a measure of how much the program must distort the unit cell dimensions
of a particular space group to force it to produce data that matches the observed data. The space
group with the highest symmetry and the lowest distortion index is selected for fitting and
optimization.
In this process of fitting and optimization, Denzo predicts where spots should appear on
the image. Fitting algorithms optimize a variety of values (crystal distance, detector distance,
crystal rotation, unit cell dimensions, mosaicity etc.) to achieve the best relationship between
spots and predictions. The quality of the fitting can be judged by visual inspection of the image
(looking to see if predictions match with actual spots) or by looking at the value for the chi-
squared goodness-of-fit test. The goal of fitting is to minimize the chi-squared value and
maximize the overlap of predictions with actual reflections. If fitting proceeds well, it is
reasonable to conclude that you have selected the proper space group and can proceed with data
processing.
The indexing of the data set for crSTS-5 was not a straightforward process. Initial
attempts focused on early frames of wedges 1-3 because they seemed to have the best diffraction.
The automated peak search function would select between 300-600 peaks per image. Running
the indexing script with large peak searches like this consistently gave unreasonable results. The
distortion indices for a number of different space groups were very low, however one of the unit
cell dimensions in each of the space groups was impossibly low (below 1 A). Reducing the
number of peaks included in the indexing produced similar results, as did hand-selecting groups
of peaks that seemed to be part of a single lattice. When the first several wedges did not work,
indexing with wedge 6 was investigated.
In some cases, having too many reflections selected by the peak search can make
indexing more difficult. Because of this, frames from wedge 6 that displayed fewer reflections
were used in indexing. For these frames, the automated peak search selected fewer than 100
peaks. Indexing these frames with this smaller set of peaks suggested that the space group might
be C2, or face-centered monoclinic, with the following unit cell dimensions: a = 218.53, b =
46.94, c = 75.25; a = 89.67, P3 = 96.41, y = 91.34 (values recorded after fitting). Fitting of
parameters proceeded well, so the space group and unit cell information were entered in the
indexing script and the frame was re-indexed. Rather than the expected space group C2, the
program now predicted a space group of P2, primitive monoclinic. However, when the
parameters for P2 were entered, C2 came up again. It was not possible to differentiate between
P2 and C2 on the basis of wedge 6, so the earlier wedges were investigated again to conclusively
determine the space group.
Since the frames in wedge 3 looked the best on the basis of visual inspection, it was
selected first. Indexing with the C2 space group/unit cell information entered suggested C2 as
expected. When the P2 information was entered and the frame was re-indexed, C2 came out as
the space group with the lowest distortion index. This was a good indication that C2 was in fact
Figure 2.14 - Overlap between spots and predictions following parameter fitting. The
yellow predictions indicate partial reflections.
the correct space group. Parameter fitting gave good overlap between the spots and predictions
as shown in Figure 2.14. At this stage, it became apparent that the mosaicity was fairly high,
possibly greater than 1.0. Even when the mosaicity was increased to 1.5, there were still some
spots that were not covered by predictions (note the low resolution regions in Figure 2.14). This
provided further evidence that there may be multiple lattices present in the crystal. Even though
this is a significant issue in data processing, the spots seemed to be far enough apart so that the
lattices should be distinguishable. Using the information from the indexing, the first three
wedges were integrated with Denzo, and the results scaled and analyzed using Scalepack.
2.4.2 Integration and scaling with Denzo/Scalepack
Integration is the process by which the intensities of the different reflections are
measured. Based on the space group and unit cell, Denzo predicts where reflections should be
and integrates the intensity of the peak in relation to the background. A weak level is set, and the
program will reject reflections below this level. Also, the program will reject overlapping
reflections. Several parameters can be optimized for integrations, including spot and background
shape and size. It is important to have the right shapes and sizes to maximize the portion of the
reflection that is measured while minimizing the reflections rejected due to overlap issues.
Following integration, scaling allows you to analyze data from a single data set or merge data
from multiple sets. Scaling assigns a scale factor to each frame included to account for
weakening diffraction due to data decay over the course of data collection. Scalepack also
performs several iterations of post-refinement, in which select integration parameters are refined.
The most notable of these is the mosaicity. Importantly, Scalepack will reject reflections that
don't seem to match and compare the symmetry related reflections. This is the first time when
the data is split into multiple resolution shells and several crystallographic statistics are
computed, including I/a, completeness, redundancy, and Rsym. The quality of the data can be
judged at the end of scaling based on the Rsym value and on the chi-squared goodness-of-fit test.
While scaling was performed on wedges 1-3, only wedge 3 will be discussed since it
provided the highest quality data. Initially, scaling gave some questionable results. The scale
factors assigned to the different frames varied a great deal, from unreasonably low to
unreasonably high. The values for mosaicity also showed a great deal of variation, as did the
chi-squared test values. These results were indicative of a problem in the script used to run
Scalepack, and were resolved when detector specific error parameters were included. Re-scaling
following the inclusion of these parameters gave much more reasonable results without having to
resort to using scale restrains. At this stage, it was discovered that the post-refinement was
giving mosaicity values of -1.0-1.1 while the integration was done with a mosaicity of 1.5.
Reducing the mosaicity used in the integration to 1.0 and re-scaling gave post-refined mosaicity
values that matched well with the initial value (ranging from 0.9-1.1).
Despite the success with the mosaicity, several issues with the scaling were not able to be
resolved. First, the program consistently rejected close to 50% of the data. Optimizing the
integration or scaling parameters was not able to reduce the number of rejected reflections.
These problems with rejection are indicative of systemic data problems that may be caused by
multiple lattices (crystal twinning) or by the decay in intensity of diffraction in later frames.
Secondly, the chi-squared goodness-of-fit test gave very high values (none below 1.0, greater
than 75 for one of the resolution shells). Related to this, the Rsym values were too large. Ideally,
Rsym should be zero because it is comparing symmetry related reflections that should be
identical. Practically this is not possible due to inherent experimental errors, so values of up to
7-8% are acceptable for overall Rsym. Overall, the Rsym for wedge 3 was 10.3% with much
higher values for higher resolution shells.
It was thought that these problems might be due to the small amount of data present in
the data set (only 36 frames in wedge 3), so data from multiple wedges was rescaled. A variety
of permutations were attempted, including wedges 1+3, 2+3, 1+2, 1+2+3. For each one of these
different tests, the scale factors, mosaicity values, and statistics were worse than wedge 3 alone.
Due to these issues, it was concluded that the data from this crystal would not yield adequate
information to solve the structure. The work with this data set did produce some useful data,
including the space group and unit cell dimensions for this crystal form. It also made clear the
difficulty posed by multiple lattices that will need to be overcome before the structure can be
solved.
Table 2.7 - Crystal parameters and statistics for data from wedge 3 and wedges 1-3 merged.
Values in parentheses are for the highest resolution shell.
Wedge 3 Wedges 1-3
Space Group C2 C2
Unit cell a = 218.14 a = 90.00 a = 218.22 a = 90.00
parameters (A) b = 46.35 p = 96.79 b = 46.57 P = 97.23
c = 74.66 y = 90.00 c = 74.82 y = 90.00
Resolution (A) 3.0 3.0
Total observations 19223 53239
Unique reflections 15126 (1500) 15486 (1547)
Completeness (%) 52.6 (59.1) 71.4 (74.9)
Redundancy 1.27(1.18) 3.43 (1.89)
Rsym (%) 10.3 (26.5) 45.8 (59.5)
I/a 9.6 (4.6) 12.5 (4.8)
2.5 R. serpentina strictosidine synthase
The enzyme strictosidine synthase has been cloned from three species of plant -
Catharanthus roseus, Rauvolfia serpentina, and Ophiorrhiza pumila." Previous work in the
O'Connor lab has focused on C. roseus because of its diverse and well characterized alkaloid
profile; as such our biochemical and enzyme engineering studies have focused on crSTS.
Previous crystallographic work has focused on the enzyme from R. serpentina (rsSTS), which is
79% identical to crSTS.12-14 Since published crystallization conditions were available for rsSTS,
this enzyme was initially selected to provide a rapid way to crystallographically characterize a
variety of different mutants and substrate mimic inhibitors/wild-type enzyme complexes.
2.5.1 Preparation of rsSTS for crystallization
rsSTS was expressed and purified similarly to crSTS as detailed in the Materials and
Methods section. One difference was that rsSTS was cloned into pET-28a with an N-terminal
His-tag instead of the C-terminal His-tag used for crSTS. This cloning and expression strategy
was selected to follow the published procedure as closely as possible. This approach required
that the His-tag be cleaved prior to crystallization because when rsSTS was previously
crystallized, the N-terminal His tag had to be removed. In pET-28a, there is a thrombin cleavage
site included between the His-tag and the N-terminus of the protein to allow for removal of the
affinity tag. Thrombin is a site specific protease which functions in the blood clotting cascade; it
recognizes the amino acid sequence Leu-Val-Pro-Arg-Gly-Ser and cuts on the C-terminal side of
the Arg residue. Because of the specificity for this sequence, it should be possible to keep non-
specific background cleavage to a minimum by optimizing the reaction time.
Initially, 20 giL samples were taken at 1,2,4,6, and 24 hrs. These were analyzed by SDS-
PAGE to determine the rate of cleavage, which would be indicated by the appearance of a
protein with a lower apparent molecular weight. A sample of uncleaved protein was used as a
Figure 2.15 - SDS-PAGE and Western blot analysis standard to show the starting
of rsSTS thrombin cleavage Cut Uncut ,1nt. I I ;,+ 1 . ) r.
Uncut C*
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minimal cleavage was apparent. This
could be for any number of reasons.
rsSTS tends to precipitate at pH values
above 7.5, so the cleavage was run at
this pH. However, thrombin's optimal
activity is at a pH value of 8.2, so this
enuld eYxnlain the lack of cleavhre
Additionally, running the reaction at 4 oC, while preferable to maintain protein stability, may be
slowing the reaction to an unacceptable speed. Fortunately, this initial reaction was not
I
discarded and SDS-PAGE analysis after 7 days showed complete cleavage. A second cleavage
reaction was set up and time points were taken at 1, 2, 3, 5, and 7 days. Cleavage appears to be
complete after 2 days with minimal non-specific cleavage. This was verified by Western blot
analysis using anti-His antibodies. It can be seen that there is a band in the uncut lane, indicating
presence of the His tag, and no band in the cut lane, indicating cleavage. The blot is slightly
over-developed, but it does appear that the thrombin cleavage has resulted in successful removal
of the His tag.
2.5.2 R. serpentina STS activity assays
Before further purification was attempted for rsSTS, activity assays were performed to
make sure that the protein was functioning properly and would yield a relevant crystal structure.
As with the crSTS assays performed before crystallization trials began, a simple qualitative assay
would be sufficient to verify the activity, so the STS colorimetric assay was attempted.
Three reactions were initially prepared: - cleaved rsSTS as the experiment and uncleaved
rsSTS/no enzyme as controls. No color was observed in any reaction following 30 minutes at 30
'C. The reactions were allowed to incubate for 48 hours; even after this long incubation period
no color was observed. Since rsSTS was used directly from the thrombin cleavage without
further purification, it was hypothesized that the Tris buffer and CaC12 present in the cleavage
buffer were interfering in some way with the reaction. rsSTS was buffer exchanged into 50 mM
NaH2PO 4 pH = 7.5 and the assays were repeated but no enzyme activity was apparent. The
assays were repeated and analyzed by HPLC to preclude any issue with the colorimetric assay.
No catalytic activity was observed, even after several hours incubation.
DNA sequencing verified the integrity of the gene, so the reason for this lack of activity
is puzzling. There are slight differences between this construct of rsSTS and the previously
crystallized/characterized rsSTS due to differences in the expression vector used. However it is
unlikely that changes in the two N-terminal amino acids left after cleavage would yield such a
dramatic loss of activity. Because of the lack of activity efforts toward crystallization of rsSTS
were halted and efforts towards the crystallization of C. roseus STS were begun. Not only would
crSTS provide the most biochemically relevant crystal structure, it was known from previous
work in the O'Connor lab that it could be easily obtained in a highly pure and active preparation.
2.6 Summary and future work
Two different forms of strictosidine synthase have been studied with the ultimate goal of
structural characterization of Pictet-Spenglerases. STS from R. serpentina was cloned,
expressed, and partially purified in the hopes that reproducing the published crystallization
conditions would provide a facile route to structures of mutants and structures with various
inhibitors/substrates bound. Problems with enzyme activity greatly slowed this particular
pathway of investigation, so R. serpentina STS was abandoned in favor of C. roseus STS.
C. roseus STS was cloned into an E. coli expression vector, expressed, and purified to
electrophoretic homogeneity. Following kinetic characterization of the His-tagged construct to
verify activity, it was subjected to sparse matrix crystal screens. The best hit from these screens
was optimized through multiple rounds of grid screening, additive screens, and macroseeding.
Data was collected for these crystals at the Argonne National Laboratories APS and processed
using the HKL2000 suite, including Denzo and Scalepack. Several issues with the data set
prevented the solving of a structure, including data decay and possible multiple lattices. It was
possible to determine the space group and unit cell dimensions, and this information can be used
to guide further data collection efforts.
Future work in this project can focus on two different areas. The first is getting a high
quality data set that can be used to solve the structure by molecular replacement with the existing
STS structure. This may be possible by simply screening more crystals for diffraction before
sending them to the synchrotron to identify single crystals that diffract well. Another possible
solution may be growing larger crystal using microseeding techniques. This may prevent of
reduce the growth of multiple lattice and greatly simplify the data processing. Finally, the cryo-
protection procedure can be further optimized, possibly including a gradual soak in increasing
concentration of glycerol. This may minimize shock to the crystals upon flash freezing.
The second area is solving the structures of interesting mutants and solving structures
with inhibitors bound. Since the mutants are all point mutations in the active site, the surface
residues and lattice contacts should not be perturbed significantly. The mutants should
crystallize in similar conditions as the wild type, although some grid screening may be necessary
to fully optimize the conditions. As far as structures with inhibitors bound, co-crystallization has
not been ruled out, even though including an inhibitor did not produce any difference in
crystallization properties. In addition to further co-crystallization experiments, soaking
experiments would be a worthwhile pursuit.
2.7 Materials and Methods
Cloning crSTS into pET-28a
The gene for STS was obtained from P. Bernhardt in a pGEM-T Easy (Roche, AmpR)
sub-cloning vector with N-terminal NcoI and C-terminal XhoI restriction sites. The gene
construct was cloned from the pGAL-MF yeast expression vector with a single nucleotide
insertion following the gene to allow expression in pET-28a with a C-terminal His tag with a
minimal linker sequence (Gly,Ser). A restriction double digest was performed on pGEM-T_STS
and empty pET-28a using the following reaction mixture:
Restriction digest: 19 pLL sterile ddH20
5 jiL 10x NEB Buffer 2
20 jtL plasmid DNA (pGEM-T_STS or pET-28a)
3 gtL Ncol
3 gL XhoI
The reactions were incubated at 37 oC for 3 hrs. Following incubation, 12.5 jiL 5x DNA loading
dye was added and the entire reaction was loaded onto a 1% agarose gel and run at 100 V for 45
minutes. After staining with ethidium bromide for 1 hr, the STS gene fragment and the cut pET-
28a plasmid were isolated using a gel extraction kit (Qiagen).
Following this, the gene fragment was ligated into pET-28a. Following the ligations, 1
gtL of the reaction mixture was added to 55 gpL electrocompetent E. coli Top 10 cells and
incubated on ice for 2 minutes. Transformation was achieved using a Bio-rad Micropulser on the
E2 setting. Following transformation, 250 tL SOC media was added and cells were recovered
on ice for -5 min. After recovery, cells were grown shaking at 37 'C for 1 hr. before the entire
250 iL was plated on LB Agar (Kan) plates. Plates were incubated for -24 hrs. at 37 oC before
colonies were picked and grown up in 5 mL liquid cultures with 30 [pg/mL Kan.
5 mL liquid cultures were grown overnight shaking vigorously at 37 oC. Plasmid DNA
was isolated using a commercial miniprep kit (Qiagen). An analytical double digest using the
following reaction mixture verified presence of the STS gene insert:
Double digest: 3 gL sterile ddH20
1 gL 10x NEB Buffer 2
4 jtL pET-28a_crSTS
1 jtL NcoI
1 iL XhoI
This reaction was incubated at 37 'C for 1 hr. before analysis by gel electrophoresis. Following
staining with ethidium bromide for -1 hr., the STS insert (approximately 1 kb) could be see in
several samples. These were submitted for sequencing using the T7 promoter primer and T7
terminator primers with the following reaction mixture:
Sequencing: 6 iiL sterile ddH20
5 gL pET-28a_crSTS
1 gtL either T7 promoter or T7 terminator primer
Sequencing verified the presence of the intact STS gene insert with the proper C-terminal
hexahistidine tag.
Expression and purification for kinetic characterization
The following buffers were used during the purification of crSTS for kinetic
characterization:
Lysis Buffer: 50 mM NaH2PO 4  Wash Buffer: 50 mM NaH2PO4
300 mM NaCl 300 mM NaCl
10 mM Imidazole 20 mM Imidazole
pH = 8.0 pH = 8.0
Elution Buffer: 50 mM NaH2PO 4  SE30 Buffer: 50 mM NaH 2PO 4
300 mM NaCI 10% glycerol
250 mM Imidazole pH = 7.5
pH = 8.0
The vector pET-28a_crSTS was transformed into E. coli BL21 (DE3) cells by
electroporation. Following the pulse, 250 jtL SOC media was added and cells were recovered on
ice for five minutes. After recovery, cells were grown shaking at 37 oC for 1 hr. before plating of
50 jtL on an LB-Agar (Kan) plate. This plate was incubated overnight at 37 oC. A 5 mL LB
broth (Ix Kan) starter culture was inoculated with cells from a single colony picked from the
growth plate. This culture was grown overnight shaking at 37 oC. Following overnight starter
culture growth, 1 mL of the 5 mL culture was added to 1 L LB broth (lx Kan). The 1 L culture
was incubated shaking at 37 'C until and O.D. of between 0.5-0.7 was reached (O.D. = A600
using fresh LB broth as a blank). Once O.D. had been reached, the temperature was dropped to
18 'C and the culture was induced with IPTG added to a final concentration of 1 mM. The
cultures were grown overnight shaking at 18 'C. In the morning, cells were harvested by
pelleting in the centrifuge at 4500 rpm for 15 min. Pellets were either used fresh or frozen and
stored at -20 "C until future use.
To obtain crSTS, cells were lysed with a combination of lysozyme and sonication. The
cell pellet was resuspended in 3 mL lysis buffer per gram pellet (wet weight). Lysozyme was
added to a final concentration of 1 mg/mL from a 10 mg/mL stock solution in water stored at 4
"C. Stirring or mild shaking at 4 oC for 20-30 minutes gently agitated the lysozyme mixture.
Following this, the lysis mixture was transferred to a 150 mL beaker packed in ice and sonication
was achieved using a Branson Digital Sonifier set at 63% tip amplitude. Is pulses were followed
by 4s rests to prevent heating of the lysis mixture for a total of 2.5 minutes total pulse time. The
lysis mixture was then transferred to 30 mL Oak Ridge tubes and centrifuged at 13,000 rpm for
50 minutes to pellet cellular debris. The supernatant was collected in 50 mL conical tubes and
the pellet was discarded.
Purification by Ni-NTA affinity chromatography was performed in batch.
Approximately 1 mL of Ni-NTA resin was used for each gram of cells lysed. Fresh resin was
washed with 100-200 mL lysis buffer before use to remove ethanol from the storage buffer. The
resin was then resuspended in -1 mL lysis buffer per mL resin initially used. The resin was
added to the supernatant in the 50 mL tubes and incubated with gentle shaking at 4 "C for 1 hr.
Following this incubation period, the mixture was added to the column and the flow-through was
collected. After collection of the flow-through, the column was washed with 2x 50 mL wash
buffer to remove weakly or non-specifically bound proteins. Finally, crSTS was eluted from the
column with 3x 10 mL 250 mM imidazole elution buffer.
Following Ni-NTA affinity chromatography, crSTS was purified to electrophoretic
homogeneity by FPLC. Size exclusion gel filtration chromatography using an SE30 column
gave poor resolution, although later fractions were achieved in sufficiently pure state for use in
kinetic assays. Using a higher resolution column (SE75 or SE200) should avoid this problem in
the future. Following size exclusion chromatography, crSTS was further purified by MonoQ
anion exchange chromatography with a gradient elution (0% B to 100% B). This gave pure
crSTS (purity assessed by SDS-PAGE). The protein was buffer exchanged into SE30 buffer for
kinetic characterization.
Expression and purification for crystallization studies
For crystallization studies, crSTS was expressed in E. coli as previously detailed and
purified by Ni-NTA affinity chromatography in the same was as for kinetic characterization.
After elution, fractions were pooled and buffer exchanged into 10 mM Tris HCI pH = 7.5 (the
crystallization buffer previously used in the crystallization of rsSTS). It was purified by MonoQ
anion exchange chromatography and size exclusion gel filtration chromatography using SE200
column (the highest resolution column available). The following buffers were used:
MonoQ A/SE200: 10 mM Tris HCI MonoQ B: 10 mM Tris HC1
0 mM NaCl 1 M NaCl
pH = 7.5 pH = 7.5
After MonoQ and SE200, fractions containing pure crSTS were concentrated in and Amicon
Ultra Centrifugal Filtration device to a final concentration of 12 mg/mL.
Assays for kinetic characterization of crSTS
The assay mixture of crSTS consisted of the following components. crSTS was diluted to its
final concentration from a 3.26 gM stock solution. The proper dilution was determined
empirically:
crSTS Kinetic Assays: 100 RL 200 mM NaH2PO4 pH = 7.00
50 IiL sterile ddH20
10 RL 40.3 mM secologanin (courtesy of P. Bernhardt)
20 [tL 10x tryptamine stock solution
20 iL crSTS
The reaction was incubated at 30 oC. At 30, 60, 120, and 180 minutes, 50 RiL aliquots were
removed and quenched with 5.5 IL 2 M NaOH. Analysis was performed by HPLC using 0.1%
TFA in H20 as buffer A and acetonitrile as buffer B. A gradient elution was used, proceeding
from 10%B to 100%B over 15 minutes. To correct for injection error, 75 jtM naphthylacetic
acid (NAA) was included in the assay buffer as an internal standard. Production of strictosidine
was measured by UV absorbance at 280 and 228 nm. In actuality, the strictosidine lactam is
produced under the basic quench conditions, however the conversion is rapid and total. For
simplicity, it shall be referred to simply as strictosidine.
Site-directed mutagenesis with C. roseus STS
Starting with pET28a_crSTS, site-directed mutagenesis was used to obtain E. coli
expression constructs for the relevant mutants (V214M, F226L, D177A). These mutants were
previously identified and are potential targets for crystallographic analysis. Primers were
obtained from Integrated DNA Technologies and were HPLC purified.
F226L: Forward - GTTGTTGTTGCTGAGCTGTTGTCCAACAGAATC
Reverse - GATTCTGTTGGACAACAGCTCAGCAACAACAAC
V214M: Forward - GAAGGAGTTGCACATGCCAGGTGGTGCTG
Reverse - CAGCACCACCTGGCATGTGCAACTCCTTC
D 177A: Forward - CTCTATTCACGACGCTTCTCCAGAAGGTG
Reverse - CACCTTCTGGAGAAGCGTCGTGAATAGAG
Site-directed mutagenesis was performed using a Stratagene QuickChange Site-Directed
Mutagenesis kit. The following reaction mixtures were used for each reaction. The V214M and
D177A reactions initially failed, so DMSO was included to prevent DNA secondary structure.
With DMSO, both V214M and D177A reactions were successful.
F226L : 5 tiL 10x Pfu Turbo Buffer D177A/V214M: 5 ýiL 10x Pfu Turbo Buffer
1.3 iL forward primer 1.3 tL forward primer
1.3 p.L reverse primer 1.3 ýtL reverse primer
1 p~L 10 mM dNTP mix 1 ttL 10 mM dNTP mix
0.6 tL pET28a_crSTS 0.6 jpL pET28acrSTS
40.8 tiL ddH20 5 giL DMSO
35.8 tL ddH20
These components were mixed in individual PCR tubes. Immediately before reaction, 1
tL Pfu Turbo DNA polymerase was added to each tube. PCR was done using a Stratagene
RoboCycler Gradient 96 with the following program:
# of Cycles Course
1 30 s, 95 "C
1-17 30 s, 95 oC
1 min, 55 'C (59 'C for V214M)
6.4 min, 68 'C (1 min per kb plasma length)
Hold Hold at room temperature
Following the completion of the PCR cycles, 1 jtL of the restriction enzyme Dpnl was
added to each reaction mixture to digest methylated DNA (the starting plasmid, but not the
mutated product). After addition of Dpnl, the reactions were incubated at 37 'C for 1 hr and
then placed on ice. Freshly thawed XL1-Blue Supercompetent cells were aliquoted out into 50
ptL portions. 1 ptL of the PCR/Dpnl digest mixture was added to each aliquot. These were
incubated on ice for at least 5 minutes. Cells were then transformed by heat shock at 42 oC for
30 s, followed by addition of 500 jiL SOC media (pre-warmed to 37 oC). Cells were allowed to
recover on ice for 2 min before incubation with shaking for 1 hr at 37 TC. After this initial
growth phase, all 500 jtL was plated onto 2 LB Agar (Kan) plates and grown overnight.
Colonies were picked and grown in liquid culture; DNA was isolated using a Qiagen miniprep
kit. DNA sequencing using the T7 promoter and T7 terminator primers as previously described
verified mutation.
Purification of crSTS mutants for crystallization studies
Both mutants were expressed and purified by Ni-NTA chromatography as described for
wild-type crSTS using the same methods and buffers. Following elution from the Ni-NTA
column, the fractions containing crSTS F226L and D177A were concentrated and transferred
into 50 mM Tris pH = 7.5, 10% glycerol (by buffer exchange or dialysis). They were then
purified further by MonoQ anion exchange chromatography using the following buffers:
Mono 0 A: 50 mM Tris pH = 7.5 Mono 0 B: 50 mM Tris pH = 7.5
0 M NaCl IM NaCl
10% glycerol 10% glycerol
Following MonoQ chromatography, the relevant fractions were collected and analyzed
by SDS-PAGE.
Colorimetric assay of STS
This assay is a coupled assay that relies on strictosidine glucosidase. Deglycosylation of
strictosidine produces an intermediate that spontaneously rearranges to give a yellow precipitate.
The reaction mixture contains excess secologanin and tryptamine. The following mixture was
used:
Colorimetric Assay: 10 jtL 10 mM tryptamine
5 gtL 40.3 mM secologanin
10 jiL 200 mM NaH2PO 4 pH = 7.00
20 gtL SG
10 tL cleaved rsSTS/uncleaved rsSTS/ddH 20
45 gLL ddH20
Following incubation at 30 oC, the yellow precipitate should form between 10 and 30
minutes.
Cloning rsSTS into pET-28a
Previous efforts at heterologous expression of rsSTS in E. coli gave very low yields.
Because of this, the codon-optimized gene (lacking the N-terminal signal sequence) was
purchased from Geneart. It was obtained in a pGA18 plasmid with the ampicillin resistance
gene. Following amplification and isolation (by miniprep) of this plasmid from E. coli Topl0
cells, a double digest was performed to obtain the gene insert. The target vector pET28-a was
digested simultaneously to prepare for the eventual ligation. The following reaction mixture was
used:
Restriction digest: 19 piL sterile ddH20
5 jiL 10x NEB Buffer 2
20 pL plasmid DNA (pGA18_rsSTS or pET-28a)
3 tL NdeI
3 gtL EcoRI
The reactions were incubated at 37 oC for 3 hrs. Following incubation, 12.5 PiL 5x DNA loading
dye was added and the entire reaction was loaded onto a 1% agarose gel and run at 100 V for 45
minutes. After staining with ethidium bromide for 1 hr, the STS gene fragment and the cut pET-
28a plasmid were isolated using a gel extraction kit (Qiagen).
Following this, the gene fragment was ligated into pET-28a. The following ligation
mixture was successful after several trials. Following the ligations, 1 jiL of the reaction mixture
was added to 55 giL electrocompetent E. coli Top 10 cells and incubated on ice for 2 minutes.
Transformation was achieved using a Bio-rad Micropulser on the E2 setting. Following
transformation, 250 gL SOC media was added and cells were recovered on ice for -5 min. After
recovery, cells were grown shaking at 37 oC for 1 hr. before the entire 250 pL was plated on LB
Agar (Kan) plates. Plates were incubated for -24 hrs. at 37 oC before colonies were picked and
grown up in 5 mL liquid cultures with 30 gtg/mL Kan. The experimental plate showed -50
colonies, while the control plate lacking the rsSTS gene insert showed no colonies.
5 mL liquid cultures were grown overnight shaking vigorously at 37 oC. Plasmid DNA
was isolated using a commercial miniprep kit (Qiagen). An analytical double digest using the
previously described reaction mixture verified presence of the rsSTS gene insert. The sequence
was verified as previously described using the T7 promoter and T7 terminator primers present in
the pET28-a vector.
Expression and Purification of rsSTS
The following buffers were used during the purification of rsSTS:
Lysis Buffer: 50 mM NaH2PO 4  Wash Buffer: 50 mM NaH2PO 4
300 mM NaCI 300 mM NaCl
10 mM Imidazole 20 mM Imidazole
pH = 8.0 pH = 8.0
Elution Buffer: 50 mM NaH2PO4
300 mM NaCI
250 mM Imidazole
pH = 8.0
R. serpentina STS was cultured and isolated similarly to C. roseus STS. Briefly, the
vector pET-28a_rsSTS was transformed into E. coli BL21 (DE3) cells by electroporation.
Following the electroporation, cells were grown shaking at 37 "C for 1 hr. before plating on an
LB-Agar (Kan) plate. This plate was incubated overnight at 37 "C. A 5 mL LB broth (lx Kan)
starter culture was inoculated with cells from a single colony picked from the growth plate. This
culture was grown overnight shaking at 37 oC. Following overnight starter culture growth, 1 L
LB broth (lx Kan) was inoculated. The 1 L culture was incubated shaking at 37 oC until and
O.D. of between 0.5-0.7 was reached. Once O.D. had been reached, the temperature was
dropped to 18 oC and the culture was induced with IPTG. The cultures were grown overnight
shaking at 18 oC. In the morning, cells were harvested by pelleting in the centrifuge at 4500 rpm
for 15 min. Pellets were either used fresh or frozen and stored at -20 oC until future use.
To obtain rsSTS, cells were lysed with a combination of lysozyme and sonication. The
cell pellet was resuspended in 3 mL lysis buffer per gram pellet (wet weight). Lysozyme was
added to a final concentration of 1 mg/mL from a 10 mg/mL stock solution in water stored at 4
oC. Stirring or mild shaking at 4 oC for 20-30 minutes gently agitated the lysozyme mixture.
Following this, the lysis mixture was transferred to a 150 mL beaker packed in ice and sonication
was achieved using a Branson Digital Sonifier set at 63% tip amplitude. is pulses were followed
by 4s rests to prevent heating of the lysis mixture for a total of 2.5 minutes total pulse time. The
lysis mixture was then transferred to 30 mL Oak Ridge tubes and centrifuged at 13,000 rpm for
50 minutes to pellet cellular debris. The supernatant was collected in 50 mL conical tubes and
the pellet was discarded.. After lysis, cell debris was pelleted by centrifugation at 13,000 rpm for
55 minutes.
Following lysis, rsSTS was purified by Ni-NTA metal affinity chromatography. Pre-
charged resin (Qiagen) was washed with lysis buffer before use to remove ethanol and
equilibrate the column. 1 mL of resin was used for each gram of lysed cells. The resin was
added to the supernatant in the 50 mL tubes and incubated with gentle shaking at 4 "C for 1-2
hrs. Following this incubation period, the mixture was added to the column and the flow-
through was collected. After collection of the flow-through, the column was washed with 100-
200 mL wash buffer to remove weakly or non-specifically bound proteins. Finally, rsSTS was
eluted from the column with 3x 10 mL 250 mM imidazole elution buffer. Fractions were
analyzed by SDS-PAGE. Elution fractions were concentrated and buffer exchanged into 10 mM
Tris-HCI before further use.
Thrombin cleavage of rsSTS
For the cleavage reaction, a Thrombin CleanCleave kit (Sigma) was used. This kit
features thrombin bound to an agarose bead. Having the thrombin bound facilitates easy
removal when the reaction is done; the beads are simply pelleted by gentle centrifugation. The
kit was used as per the manufacturers instructions. The resin was obtained as a 50% (v/v)
suspension of resin in 20 mM Tris-HCI pH = 8.2, 50% glycerol. 100 jtL of this slurry was
aliquoted into a 1.5 mL Eppendorf tube and spun at 2500 rpm to pellet the resin. The
supernatant was decanted, and the resin was resuspended in 500 giL Ix cleavage buffer (10x
cleavage buffer = 500 mM Tris-HCI pH = 8.0, 100 mM CaCI2). This was spun at 2500 rpm to
pellet the resin and the supernatant was decanted. This step was then repeated. Following
washing, the resin was resuspended in 100 tL 10x cleavage buffer. 900 jtL rsSTS was added to
this to give a final concentration of lx cleavage buffer and -2.5 mg/mL Ni-NTA purified rsSTS
(as determined by A280). The cleavage reaction was incubated at 4 oC with gentle shaking. To
monitor the reaction, the resin was pelleted and an aliquot was removed for SDS-PAGE analysis.
The resin was then resuspended and the reaction was allowed to proceed.
Western blotting to verify thrombin cleavage
To verify the success of the thrombin cleavage, a Western blot was performed with anti-
His antibodies. Following SDS-PAGE analysis, the protein was transferred to a nitrocellulose
membrane without Coomassie blue staining. This was done with Towbin's transfer buffer,
which includes 100 mL 10x TG (25 mM Tris, 192 mM glycine, pH = 8.3), 200 mL MeOH, and
700 mL ddH20. Transfer was done at 4 oC at 100 V for one hour. After transfer, the
nitrocellulose membrane was blocked overnight using 5% freeze-dried milk in TBS (Tris
buffered saline).
Once blocking was complete, the membrane was washed with TBST (TBS, 1% Tween-
20) two times for 10 minutes each. TBST was added to cover the membrane and the washes
were performed with gentle agitation. Following this, the membrane was incubated with a
1:1000 dilution of anti-pentaHis antibody (Qiagen) in TBS for one hour. After this, the
membrane was washed with TBST three times for 10 minutes each. The membrane was then
incubated with a 1:1000 dilution of AP (alkaline phosphatase) tagged anti-mouse antibody in
TBS for one hour. Subsequently, the membrane was washed with TBST two times for ten
minutes and TBS once for ten minutes. Finally, the membrane was incubated with NBT/BCIP
(Nitro-Blue tetrazolium chloride/5-bromo-4-chloro-3'-Indolyphosphate p-toluidine salt) that
reacts with alkaline phosphatase to produce a purple/black insoluble precipitate. After staining
was complete, the reaction was quenched with -1 mM EDTA in TBS. The membrane was dried
and fixed on parafilm and scanned to visualize.
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3. Norcoclaurine synthase crystallization studies
In addition to the monoterpene indole alkaloids, another broad class of plant derived
alkaloid natural products is the benzylisoquinoline alkaloids. This class of natural products
includes morphine, one of the most prevalent opiate analgesics isolated from poppy, and
papaverine, a vasodilator also isolated from poppy.' They are similar to terpene indole alkaloids
in that the biosynthesis begins with a Pictet-Spengler reaction, however the substrates and
enzymes are different. Benzylisoquinoline biosynthesis begins with the coupling of dopamine
and 4-hydroxyphenylacetaldehyde to yield norcoclaurine; this reaction is catalyzed by the
enzyme norcoclaurine synthase (NCS). 2-4  Structural characterization of NCS would be
interesting for several reasons, including the ability to illuminate general features of Pictet-
Spenglerases, so efforts towards the crystallization of this enzyme were begun.
3.1 Assay design and substrate synthesis
Before crystallizing an enzyme, it is important to show that it is active to ensure that the
structure will provide biologically relevant information. As such, the first step towards
crystallizing norcoclaurine synthase was assaying it for function. Several different groups have
studied NCS recently and have employed several different assays designs with unique detection
methods. These include a radiolabeled TLC assay (Faccini), a chiral LC/MS assay (Sato), and a
circular dichroism (CD) spectroscopy based assay (Tanner).3'5'6 Because of availability of
instrumentation and relative ease compared to the other assays (i.e. no radiolabels were
necessary), the LC/MS assay was selected for development.
3.1.1 Synthesis of 4-hydroxyphenylacetaldehyde
The first step towards assaying the enzyme for function was the synthesis of the substrate
4-hydroxyphenylacetaldehyde (4-HPAA). This starting material is unstable and sensitive to
oxygen, which causes oxidation from the aldehyde to the carboxylic acid. There are several
different ways of making 4-HPAA. In their assays, Facchini and Tanner use the Doering-Parikh
oxidation to oxidize 4-hydroxyphenethyl alcohol. Sato, on the other hand uses an enzymatic
method that oxidizes tyramine using commercially available tyramine oxidase from Arthrobacter
(Sigma). Because of the apparent ease of this method and the simple work-up, Sato's enzymatic
oxidation was attempted first to make 4-HPAA.
Using this preparation of 4-HPAA did not result in product formation, either from
enzymatic reaction or from non-enzymatic chemical reaction. Since this enzymatic method for
making 4-HPAA failed, chemical methods for the synthesis of 4-HPAA were investigated.
One of the traditional routes to the synthesis of aldehydes is oxidation using pyridinium
dichromate (PDC). PDC is
Scheme 3.1 - PVPDC synthesis of 4-HPAA.
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very similar to pyridinium chlorochromate. The drawback to synthesis of 4-HPAA by PDC
oxidation is the extensive work-up required to remove the spent chromium reagent. This can be
simplified by using a polyvinylpyridinium resin bound PDC, called PVPDC. Work-up for
PVPDC oxidations consists of filtering and washing the resin because the product will be soluble
in the correct solvents while the catalyst will remain bound to the resin.
Following PVPDC synthesis of the aldehyde, the enzymatic assays were still not yielding
the expected results. As before, no reaction was seen, either as a decrease in one of the starting
material peaks or a growth of one of the product peaks. The lack of background reaction is most
troubling, because dopamine and 4-HPAA should react readily under the assay conditions (37
'C, pH = 7.0). A literature search provided an array of different conditions under which
dopamine and 4-HPAA should undergo chemical reaction.7  Several attempts were made to
show background reaction using these conditions, which involved changing the buffer from Tris
to phosphate, varying the temperature, and varying the pH. None of the conditions tested
showed chemical reaction.
Figure 3.2 - Representative HPLC time course showing lack of activity. Each trace
is a time point, progressing from 90 - 240 minutes moving upwards. The first large
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The authentic standard for 4-HPAA was purchased from Toronto Research Chemicals.
When obtained, it was dissolved in EtOAc to give a 20 mM stock solution, which was stored at -
80 TC. It can be seen from HPLC analysis that there are two peaks, even in the standard. One of
these is the aldehyde; the other is most probably the acid. The acid has not been characterized,
but it is known that aldehydes such as 4-HPAA will spontaneously oxidize under ambient
oxygen concentrations. It can be seen from the HPLC trace in Figure 3.3 that the single peak in
my 4-HPAA corresponds to the second peak in the authentic standard. From reaction data, it
appears that the first peak is the substrate (it is consumed), while the second peak is the acid (not
consumed in the assys). With this new information, it was decided to use the authentic standard
in all further assay reactions.
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3.1.2 Monitoring the assay
Initially, it was thought that replicating Sato's LC/MS based assay would give the
quickest results. This method uses a chiral CBH (cellobiohydrolase) column with mass
spectrometric detection to monitor product formation (m/z = 272 [M+H]). The CBH column is
run with an isocratic gradient using 0.3% acetic acid buffer adjusted to pH = 4.7. It is important
to use a volatile base when adjusting the pH of buffers intended for use on the LC/MS; the
NaOAc salts formed when NaOH is used do not fly and result in a rapid deterioration of the mass
spectrometer. Initial attempts did not show production of product on LC/MS, and it was thought
that the reaction components were eluting with the solvent front. To remedy this, the pH of the
running buffer was varied within the limits of the column (pH = 4.3 - 5.3). When this did not
remedy the problem, it was thought that the product might not fly well with the electrospray
ionization method employed. It is now clear that the real problem was with the 4-HPAA starting
material; a recently obtained norcoclaurine standard (Sequoia Natural Products) flies well on the
LC/MS. However, at the time it was thought best to transfer the assay to HPLC and employ
UVNis detection to monitor product formation.
Following transfer of the assay to the HPLC, the first step was to optimize the elution
gradient. Standard HPLC buffers were used (Buffer A = 0.1% TFA in H20, Buffer B =
Acetonitrile). The first gradient employed went from 10% B to 100% B over 15 minutes (the
standard gradient used for separating tryptamine, secologanin, and strictosidine). With this
gradient, there was poor resolution of the starting materials. The gradient was optimized to a
much shallower 5% B to 30% B over 15 minutes to allow for good separation of the starting
materials (and the norcoclaurine standard, once it was obtained). However, even with separation
of the starting materials, no product formation was observed. It was at this point that the
chemical test reactions were attempted and monitored by HPLC. The failure of these reactions
revealed that the lack of product was due to the inability of the starting materials to react, not the
monitoring method.
Once the standard for 4-HPAA was received, the enzymatic assays were redone using the
two new His-tagged constructs of T. flavum NCS (N-terminal and C-terminal tags) and
monitored by HPLC. For this new set of experiments, the disappearance of starting material and
the appearance of product were clear. However, enzyme controls revealed a substantial
background reaction that would complicate any characterization of the kinetic parameters
performed using HPLC detection. Lowering substrate concentrations to the detection limit of the
instrument did not give reduction in the background reaction as compared to the enzymatic
reaction for either construct. It became apparent that the background reaction was too fast to be
differentiated from the enzymatic reaction at substrate concentrations amenable to HPLC
visualization. As such, the assay has been moved backed to the LC/MS and optimized to allow
the enzymatic reaction to be successfully monitored (done by W. Runguphan).
3.2 T. flavum noreoclaurine synthase
As discussed in the introduction, there are several different forms of NCS. The first NCS
isolated comes from plant species Thalictrum flavum (meadow rue), and from here on will be
referred to as tfNCS. tfNCS is a -25 kDa proposed dimer with no dependence on any metals or
cofactors. It shows no homology to cjNCS, STS, although it does show significant homology
(50-60%) with class 10 pathogenesis related proteins (PR10) that seem to play a role in defense
against pathogens. 6' o Most interesting is the lack of homology to cjNCS because these two
enzymes have the exact same substrates and function in the same biosynthetic pathway of
benzylisoquinoline alkaloid biosynthesis. A structural characterization of this enzyme could
provide insight into general mechanisms of catalysis or general structural motifs for Pictet-
Spenglerases. Also, a comparison of the structures of the two apparently unrelated enzymes
tfNCS and cjNCS could provide interesting insight into why two radically different enzymes
evolved to catalyze the same reaction in the same biosynthetic pathway.
3.2.1 Expression of T. flavum NCS
A synthetic gene encoding the full length tfNCS protein was cloned into the E. coli
expression vector pET-28a. Following expression and cell lysis, purification was attempted by
Ni-NTA affinity chromatography. However, tfNCS was not expressed in E. coli. It can be
concluded that the 19 amino acid N-terminal signal peptide is an impediment to heterologous
expression, even when masked by the N-terminal His tag. It probably would have presented a
problem for crystallization as well; signal peptides are often unstructured regions of the protein.
To remedy this situation, the signal peptide was removed by site-directed mutagenesis. In
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signal sequence, multiple other
tfNCS constructs were made.
These include and N-terminally and
C-terminally tagged versions of the
truncated protein (called
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tfNCSA19_Nterm and tfNCSA19_Cterm respectively). The new constructs were expressed,
purified, and assayed by W. Runguphan. Following Ni-NTA purification using a Qiagen spin
column kit highly pure protein was obtained, as shown in the gel in Figure 3.4.
This protein was assayed for function and monitored by either HPLC (W. Hillmann) or
LC/MS (W. Runguphan). Attempts to characterize this enzyme using and HPLC based assay
were not successful. With the correct substrate, the background reaction was substantial. Since
the HPLC has a relatively poor detection limit (iM), high concentrations of the substrates were
required to visualize the reaction.
tfNCSdl9_Cterm time course At these high concentrations, the
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substrates were used. The assays of the two constructs using the optimized LC/MS assay
showed that the C-terminally tagged construct was more active than the N-terminally tagged
construct. For this reason, tfNCSA19_Cterm was selected for crystallization experiments.
3.2.2 Dynamic light scattering
Sparse matrix screening for initial conditions can be a difficult process due to the
multitude of different variables that may be varied and optimized. These include the protein
concentration (from 2-30 mg/mL), pH of the storage buffer, screening temperature (r.t. or 4 oC),
concentration of the commercial screening conditions (full or half strength), mother liquor
volume, hanging drop volume, etc. One way to minimize this process is to screen the protein to
by crystallized for optimal solubility using dynamic light scattering (DLS). In brief, this
technique measures the aggregation properties of small particle in solution. Laser light is passed
through a sample and a photomultiplier tube monitors the light scattered at 900. Analysis of the
results can provide several different values; the most important value for crystallography is the
Figure 3.6 - Representative data for tfNCSAl9_Cterm DLS screening.
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polydispersity." A lower polydispersity corresponds to a more uniform solution. Since more
uniform protein preparations have been shown to crystallize better than polydisperse samples,
the goal of DLS is to find the buffer in which the protein has the lowest polydispersity value.
For crystallographic purposes, ideal polydispersity values are less than 15%. 12
In preparation for DLS screening, tfNCSA19_Cterm was buffer exchanged from Ni-NTA
elution buffer into 10 mM NaH2PO 4 at pH = 7.0 and concentrated to 27 mg/mL (measured by
A280). This buffer has been used in previous protein preparations used for activity and
mechanistic studies.4 6 The protein was then buffer exchanged into an array of different buffers
for screening. Each of these buffers was adjusted to an appropriate pH with the buffer range at
which the protein should be stable. The final concentration of the protein was diluted to 0.68
mg/mL with each test buffer. Results of the DLS screening can be seen in Table 3.1
Table 3.1 - DLS screening results
Buffer pH Polydispersity (%) Mass of smallest radius peak
25 mM MOPS 7.0 13.9 97%
25 mM TES 7.0 15.7 96.9%
25 mM Bis-Tris 7.0 25.8 98.9%
25 mM Bicine 7.0 19.2 99.2%
25 mM MES 6.5 13.9 99.6%
25 mM HEPES 7.0 12.1 71.7%
10 mM TrisHC1, 100 mM NaCl 7.5 26.2 98.5%
10 mM NaH2PO 4 7.0 55.8 100%
From these results, it can be seen that several different buffers have polydispersity values
in the acceptable range (<15%), including MOPS, TES, MES, and HEPES. However, while all
four buffers show a large mass percentage peak at the lowest radius, HEPES has a large higher
radius peak which accounts for almost 30% of the mass (DLS cannot accurately assign values for
the radii of proteins in solution, but it can provide relative measurements of species that are far
enough apart in size). The first and smallest peak is presumed to be tfNCSAl9_Cterm and the
second peak is presumed to be due to aggregation or microscopic precipitation of the protein.
For this reason, only MOPS, TES, and MES were selected for further work. Protein samples
were buffer exchanged into the appropriate buffers and concentrated. For MOPS and MES,
protein precipitated rapidly above 1 mg/mL. For TES, the protein was soluble and was
ultimately concentrated to 10 mg/mL. This protein was used for crystallization trials.
3.3 Crystallization experiments with A19 T. flavum NCS
3.3.1 Sparse matrix screening for initial conditions
The protein preparation used for crystallization screens contained Ni-NTA purified
tfNCSAl9_Cterm in 25 mM TES pH = 7.0. The Hampton Research Index Screen (HR-1440 and
Hampton Research Crystal Screen 1 (HR-110) and Crystal Screen 2 (HR-112) were initially set
up using the hanging drop vapor diffusion method as previously described. Protein at a
concentration of 10 mg/mL was initially used. 500 [tL mother liquor was used in each well with
3 piL hanging drops (1.5 piL mother liquor, 1.5 pjL protein).
Table 3.2 - Sparse matrix screening results for tfNCSA19 Cterm
Screen Concentration Temperature Results
(mg/mL)
Index 10 r.t. A large number of wells showed heavy
precipitation almost immediately. For the
remaining drops, phase separation and
granular precipitants were the most common
results.
Hit: Condition #71 (0.2 M NaC1, 0.1 M Bis-
Tris pH = 6.5, 25% w/v PEG 3350)
Crystal Screen 1 10 r.t. Immediate heavy precipitation was seen in the
majority of drops. Some granular precipitates
and some clear drops.
Crystal Screen 2 10 r.t. Immediate heavy precipitation was seen in
many drops. Clear drops, phase separation,
and granular precipitates dominated the rest.
Index 5 r.t. Fewer drops showed heavy precipitate,
although many still did. Phase separation was
still common, as were granular precipitates.
More drops remained clear.
Hit: Condition #17 (1.26 M NaH2PO 4 'H 20,
0.14 M K2HPO4, pH = 5.6)
Immediately after setting up the initial screens, heavy precipitate was observed in a large number
(-50%) of wells, so the Index screen was repeated at a lower protein concentration of 5 mg/mL.
Screens were monitored at 2, 6, and 9 days (Index and Crystal screens at 10 mg/mL) or 1, 4, and
6 days (Index screen at 5 mg/mL). Results of the initial screening are summarized in Table 3.2.
Several hits were obtained from the initial screening of tfNCSA19_Cterm. The first was
observed after six days in the 10 mg/mL Index screen. After two days, this well showed clear
phase separation. Over the course of the next several days, the protein that was not consumed in
the initial phase separation crystallized, giving crystals with a long needle-like morphology. One
such needle cluster was observed after six days, with two more seen following observation on
day nine. The other hit was seen after one day in the 5 mg/mL Index screen. Upon the first
observation, small spherules were seen in the drop. Over the next several days, these grew larger
and began to show a rectangular three-dimensional morphology (small prisms). Notably, the
lower concentration Index screen did not show the same hit as the higher concentration screen in
condition 71. The second screen showed phase separation as the first, but there was evidently
not enough protein to continue on to form crystals at the lower concentration. Since these hits
represented the best results from the initial screens, both were further optimized.
Figure 3.7 - Initial hits for tfNCSAl9_Cterm. a) Index #71, 10 mg/mL;
b) Index 17, 5 mg/mL
3.3.2 Optimization of initial hits
Because of their superior morphology, initial grid screening efforts were focused around
the hit from condition 17 at 5 mg/mL. The crystals produced in the initial hit did not stain well
with Izit dye (as shown in Figure 3.8), and they
were not large enough to use for SDS-PAGE
analysis. It was hoped that reproducing and
optimizing the crystals would yield enough for
analysis and characterization. A grid screen was
constructed in a 24 well plate and featured wells with the initial hit mother liquor and progressive
dilutions of the mother liquor solution (90% mother liquor, 70%, 50%, 30%, and 10%). In
addition to the range of dilutions, both 3 jtL total and 4 jtL total drops were used (4 tL drops = 2
tL protein solution, 2 gpL mother liquor). Larger drops have longer equilibration times and can
sometimes lead to better and larger crystal growth. Unfortunately, none of the conditions
resulted in reproduction of the crystal.
In view of the failure to reproduce the initial hit from condition 17, the hit from condition
71 at 10 mg/mL was investigated. A main goal of this optimization was to make the crystals
larger and improve morphology. Thin needles are less than ideal for any sort of X-ray studies.
Grid screening focused on adjusting the concentrations of NaCl and PEG 3350. Also, several
grid screens were performed at 4 'C to test whether or not lowering the temperature would have a
positive effect. Early screens focused on a broad coverage of the parameter space by widely
varying the concentrations of the components. For instance, in the first grid screen the
concentration of PEG 3350 was varied from 10% - 25% and the concentration of NaCl was
varied from 50 mM - 200 mM. Results from this screen showed that lower concentrations of
both PEG 3350 and NaCl resulted in improved crystallization. Notably, at lower precipitant
concentrations the amount of phase separation decreased until it no longer occurred. Also, at
lower precipitant and lower salt concentrations the morphology of the crystals changed from thin
needles to small, yet three dimensional, prisms. Conditions were optimized from 200 mM NaC1,
20% PEG 3350 to 0 mM NaCl, 1% PEG 3350. The optimized conditions yielded small crystals
Figure 3.9 - Improvement of tfNCSA 19_Cterm crystals by grid screening. a) Initial hit;
b) 50 mM NaCl, 5% PEG 3350; c) 0 mM NaCl, 1% PEG 3350; d) Zoom view of c.
(- 20 glm x 10 gtm x 10 Uim) with the predominant morphology being that of rectangular pnsms.
The progression of the grid screening is illustrated in Figure 3.9.
3.3.3 Co-crystallization experiments
Co-crystallization of proteins with inhibitors or substrates present is an established way to
improve crystallization. This is because the presence of a substrate/inhibitor can reduce
structural disorder by binding to the protein and stabilizing a particular conformation. The
stabilized protein can then make more lattice contacts and stronger lattice contacts; the result
being better and larger crystals. For tfNCSA19_Cterm, there are three potential substrates that
can be used in co-crystallization experiments. These include the natural substrates dopamine and
4-HPAA (in different drops to prevent turnover), as well as a substrate analog of 4-HPAA called
2-(4-hydroxyphenyl)-ethanol (HPE). This substrate analog is a reduced form of the aldehyde
substrate 4-HPAA and is commercially available. In the recent NMR based homology model of
tfNCS, this substrate was shown to induce substantial chemical shifts, so could provide much
needed stability to the protein.13
The co-crystallization experiments were performed in the same manner as previously
described grid screens. Several hours before setting up trays, the protein was incubated with the
desired additive (1 mM dopamine, 1 mM 4-HPAA, 1 mM HPE) for several hours at 4 oC. In
addition to the new additives, a range of PEG 3350 concentrations were investigated, from 0.1%
- 6 %. Finally, drops were also set up with native protein (no additive) as a control for crystal
formation. Screens were incubated at room temperature and observed every few days to monitor
crystal formation.
As before, concentration of PEG
Figure 3.10 - Results of additive 
screening
with HPE. a) Crystals after 1 week; b) Zoom 3350 above 1% resulted in a large number
Al) 7nnm view nf c
(-100) of very small crystals. PEG 3350
concentrations below 1% resulted in
negligible crystal growth within one week
(the time scale of previous crystal
formation). It seems that 1% PEG 3350 is
the most optimal concentration. As
expected, the drops set up without any
additives crystallized in the same way as
before, giving small crystals. Drops with
A4-IPAA shnoxred h•nvv nreicinitatinn This
is not surprising, since 4-HPAA reacts readily with oxygen and probably degraded rapidly in the
well. Also, 4-HPAA is only soluble in organic solvent, so a small amount of ethyl acetate was
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present in the drop. Since the 4-HPAA was added from a 20 mM stock solution, there was only
-0.5% EtOAc in the protein and -0.25 % in the drop. However, this was obviously enough to
negatively affect the crystallization properties.
In contrast to the drops with 4-HPAA, those with dopamine and HPE showed marked
improvement in crystallization. Crystals formed first in the drops with HPE (Figure 3.10).
These were much larger than the native crystals (approximate dimensions of 75 gtm x 50 gim x
10 gtm including the additive). Like previous tfNCSA19_Cterm crystals, these crystals did not
stain well with Izit dye, although the crystals did seem to develop a darker blue color after an
extended incubation (several days). Unfortunately, following the addition of the Izit dye the
drop showed no further crystal growth (either new crystals or existing crystals growing larger).
For the dopamine containing drops, crystals took several additional days to form. These crystals
were allowed to grow without disturbance and appeared to become slightly larger over the course
of time. The dimensions after -two weeks were approximately 100 gm x 50 gim x 20 jim.
Morphology of these crystals was consistent with the previously observed morphology for the
native crystals and for the HPE crystals. At this time, characterization of the crystals by SDS-
PAGE would confirm that they are in fact protein crystals. However, until high quality crystals
of this nature are reproduced, sacrificing crystals for gel analysis would not be prudent. In light
of these results, multiple drops were set up containing 0 mM NaCl, 1% PEG 3350, either 1 mM
dopamine, 1 mM HPE, or 1 mM dopamine + 1 mM HPE. The results of this screen are pending.
3.4 C. japonica norcoclaurine synthase
In 2007, a new version of NCS was isolated from Coptis japonica cell lines selected for
their high alkaloid production.5 This new form of NCS, referred to as cjNCS from here on, is a
-40 kDa monomer with some very interesting features. It showed no sequence homology to
previously characterized forms of NCS or to STS, however it did show homology to 2-
oxoglutarate dependant non-heme iron monooxygenases. Assays of this enzyme (both native
and heterologously expressed) showed that its activity was dependant on ferrous iron, but not on
2-oxoglutarate and oxygen. This is an extremely unusual and unprecedented result.
Structural characterization of cjNCS should yield a great deal of insight into its
mechanism. For instance, what is the role of iron? Is it catalytic, structural, or does it facilitate
proper binding of substrates? Since STS and NCS are the only known Pictet-Spenglerases,
characterization of NCS should also allow for some generalizations to be made about Pictet-
Spenglerases in general. Despite the different sequences are there common structural motifs in
this class of enzymes shares? For these reasons, attempts towards a structural characterization of
cjNCS were begun.
3.4.1 Expression and thrombin cleavage of C. japonica NCS
Unlike tfNCS, cjNCS did not feature a predicted N-terminal signal peptide. The full-
length gene was ordered (Geneart) and cloned into the E. coli expression vector pET-28a with an
N-terminal hexa-histidine tag and a thrombin cleavage site for affinity purification tag removal.
Expression and purification of cjNCS proceeded uneventfully. The protein over-expressed well
under IPTG induction and was purified to electrophoretic homogeneity by Ni-NTA metal affinity
chromatography, MonoQ anion exchange chromatography, and SE200 size exclusion
chromatography. Gels showing the various stages of purification are shown in Figure 3.11.
In preparation for activity assays and crystallization, the His-tag was removed by
thrombin cleavage. This was accomplished using agarose bound thrombin kit as described for
rsSTS. SDS-PAGE analysis of samples collected at 1, 3, 18, and 24 hours revealed incomplete
cleavage of the tag (as measured by a decrease in apparent molecular weight of the cleaved
protein). The reaction was purified by passing the protein over an Ni-NTA column and
collecting the flowthrough (flowthrough should contain cleaved protein, while any uncleaved
protein should remain bound to the column). This protein was concentrated to 2 mg/mL in 50
Figure 3.11 - Purification of cjNCS. The left gel shows fractions after
Ni-NTA chromatography, the right after gel filtration chromatography.
mM Tris-HCI pH = 7.5 (verified by both A280 and Bradford assay) and used for activity assays.
3.4.2 Enzyme activity assays
Initially, it was thought that it would be a simple task to repeat the assays presented in by
Sato.5 Even though cjNCS is a non-heme iron protein, Sato did not perform any reconstitution
steps following purification of heterologously expressed protein from E. coli. Also, the assay
procedures seemed to be fairly straightforward. A full kinetic characterization was not the goal
of these assays. Simply showing activity would be sufficient before moving on to crystallizing
cjNCS. Following the purification procedure, both cleaved and un-cleaved cjNCS were
subjected to enzymatic activity assays.
Initially, no activity was seen by LC/MS. Several different buffers were used as
previously described. However, no appreciable difference was seen based on this change. It was
at this time that the assay monitoring platform was switched from the LC/MS to the HPLC.
After optimizing the elution gradient to separate the starting materials, there was still no product
formation seen. At this point, a variety of different quenches were investigated. These included
a TFA quench, a methanol quench, and a temperature quench. Although there were no
differences visible by HPLC, the temperature quench was selected as the least likely to perturb
and obscure the system. Also, the methanol quench substantially diluted the reaction making
product visualization more difficult. Assays with increased substrate concentrations (up to 5 mM
for one of the substrates) also showed no reaction, either enzymatic or background.
At this time, it became apparent that there might be an issue with the substrates in the
reaction (specifically the 4-HPAA). While this was investigated, efforts towards showing cjNCS
activity were continued. It was a possibility that the lack of activity might be due to the lack of
iron in the enzyme. To supplement iron, assays were set up with either FeCl2 or FeCl3 added to
supplement the enzyme. HPLC analysis showed a mixture of products, however nothing which
corresponded to the norcoclaurine standard. It was concluded that if lack of iron was the
problem, a more sophisticated reconstitution procedure would be required.
In retrospect, the reason why there was no reaction is that the 4-HPAA was actually the
acid 4-hydroxyphenylacetic acid. No knowing this, several new constructs of cjNCS were
planned. These included an N-terminal and C-terminal FLAG tag (a non-metal binding affinity
tag), as well as an untagged version of the protein (the initial published heterologous expression
was of an untagged construct).
The new constructs were made by cloning the cjNCS gene out of the pET-28a plasmid
using primers with the desired tag appended on to the desired end (N-terminal or C-terminal).
After the PCR was complete, each sample was purified using a Qiagen PCR clean-up kit and
analyzed by 1% agarose gel electrophoresis, shown in Figure 3.12. Samples that showed DNA
fragments of the appropriate sized were selected and sub-cloned into a pGEM-T Easy transfer
vector. The pGEM-T Easy system includes a convenient blue/white screening method for
selecting successful ligations. The pGEM-T vector contains the LacZ gene (beta-galactosidase).
When ligation is successful,
Figure 3.12 - PCR results for cjNCS-FLAG
the gene insert disrupts LacZ;
when the plasmid closes on
itself, the LacZ gene remains
intact. When grown on media
pre-treated with IPTG and X-Gal, colonies from successful ligations will be white while those
with closed plasmid will be blue. White colonies were selected and cultured. The plasmid DNA
was isolated my miniprep and analyzed by a restriction double digest, shown in Figure 3.13.
Successful samples (lanes 1, 4, and 5 in the figure) were sequenced to verify the success of the
cloning. A mutation in the FLAG tag sequence was identified and remedied by site-directed
mutagenesis. Repeat sequencing verified the integrity of
the gene.
The N-terminal FLAG tag, C-terminal FLAG
tag, and untagged constructs were expressed and
partially purified by W. Runguphan. All three of these
constructs show catalytic activity above the background
reaction, with the untagged construct and the C-
terminally tagged construct showing slightly better
activity than the N-terminally tagged construct.
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Monitoring the reaction with a CBH chiral column shows that the enzyme produces (S)-
norcoclaurine stereoselectively. Interestingly, this stereoselectivity seems to decrease over time.
Investigations into this phenomenon are on going.
3.5 Summary and future work
Two different forms of norcoclaurine synthase have been studied with the ultimate goal
of structural characterization of Pictet-Spenglerases. Each enzyme, tfNCS and cjNCS, has
presented its own unique set of issues, and progress has been made towards crystallizing these
enzymes. The first step was the design and optimization of an assay method. 4-HPAA, the
aldehyde substrate, was difficult to obtain. Enzymatic and synthetic methods were attempted
before a standard became commercially available. Many of the early difficulties experienced
working with these enzymes may have been due to the inclusion of an oxidized substrate instead
of the proper aldehyde in the reaction mixtures. Also important was determining a proper
method to monitor the assay. The assays began on the LC/MS, moved to the HPLC, and then
back to the LC/MS when it became apparent that the background reaction would obscure
enzymatic activity on the HPLC. With a reliable assay, progress has moved forward much more
rapidly on this project.
Initially, expression of tfNCS was attempted with the full-length gene. The presence of a
19 amino acid N-terminal signal peptide prevented expression in E. coli (and likely would have
negatively impacted crystallization). After the removal of this signal peptide by site-directed
mutagenesis, two different constructs were cloned featuring N- and C-terminal hexa-histidine
tags. Assays revealed that the C-terminally tagged construct was more active, so it was selected
for crystallization studies. Sparse matrix screening identified several hits, one of which was
optimized through grid screening and co-crystallization to produce crystals with rectangular
prism morphology that are approximately 100 x 50 x 20 gtm. Future work with this project
involves full characterization of these crystals and screening for diffraction. Once high quality
diffraction data is obtained, molecular replacement may be performed with the recent NMR
based homology model of tfNCS or birch pollen allergen Bet vl (the template for the homology
model). If molecular replacement does not work, phase information may be obtained through
Se-Met derived protein for MAD/SAD experiments or using heavy atom derivatives for
isomorphous replacement. Recently, a report detailing tfNCS crystallization has been published,
however there is no structure available yet.14 As such, work on this project will continue.
Following cloning, expression of cjNCS and the thrombin cleavage of the N-terminal
His-tag were completed. Activity assays of the cleaved protein did not exhibit any catalytic
activity. Despite trying to vary and optimize many different factors of the assay (monitoring
method, chromatography conditions, quenching method, addition of exogenous iron), cjNCS did
not appear to function at any time during the assays. Several new constructs were cloned and
subjected to the assay procedures that were used to show tfNCSA19 activity. All three of them
show activity above the background reaction, but there are unresolved issues with the assay,
namely the loss of stereoselectivity over time. Future work with this enzyme involves a more
detailed study of its activity, including determining why the stereoselectivity decreases. Also,
the purification needs to be optimized to yield crystallography quality protein. Once this is
completed, sparse matrix screens can begin to identify initial conditions for crystallization.
Since only one Fe is present per protein molecule, Fe MAD would probably not give sufficient
phase information to solve the structure. However, Se-Met derived protein or heavy atom
derivatives should give this information.
3.6 Materials and Methods
Enzymatic Synthesis of 4-HPAA
Tyramine oxidase (Sigma) was stored as a 2 U/mL stock solution in 50 mM Tris-HC1, pH
= 7.5 at 4 oC. An aliquot was also frozen and stored at -20 oC for long-term storage. To make 4-
HPAA, 100 giL 2 U/mL tyramine oxidase was added to a 4 mM solution of tyramine. This was
incubated at 37 oC for 2 hours. The reaction was then boiled for 5 minutes and centrifuged to
remove the enzyme. The reaction was assumed to proceed with a quantitative yield; the final
mixture (after boiling) was frozen at -80 oC to be used as a 2 mM 4-HPAA stock solution.
Synthesis of 4-HPAA by PDC Oxidation
PVPDC resin (Fluka) contains 2.2 mmol/g chromate. 1.9 g resin (4.2 mmol chromate)
was suspended in water and stirred vigorously for 2-3 hours to properly wet the resin. The water
was filtered off and the resin was washed with water to removed unbound chromate. The moist
resin was added to a 50 mL round bottom flask and 15 mL cyclohexane and a Teflon coated stir
bar were added. 143 mg (1.03 mmol) 4-hydroxyphenyethyl alcohol was added to this. The flask
was sealed under inert atmosphere and refluxed at 70 oC for 16 hrs. Resin was removed by
filtration and washed with dichloromethane and ethyl acetate. This was concentrated to give a
yellow oil that was further purified by flash silica gel chromatography in 9:1
chloroform:methanol. Three spots were evident on TLC and each was isolated. The TLC plates
were visualized with UV light and by DNP aldehyde stain. Only one spot stained when exposed
to DNP; this spot was isolated and the solvent removed under reduced pressure. This resulted in
89 mg product, for a yield of 64%. This product was dissolved in a 25% DMSO/water mixture
to give a 20 mM stock solution that was stored at -80 oC. A proton NMR shows what appears to
be the correct product, although there are some unidentified peaks that are troubling.
General enzymatic assays of NCS
Several different NCS assays were used over the course of these experiments. As
procedures were optimized, the assays changed radically. The final optimized assay employed
for HPLC detection is as follows:
General NCS assay: 100 giL 200 mM NaH2PO 4 pH = 7.00
10 jpL 20 mM Dopamine
10 piL 20 mM 4-HPAA
20 piL enzyme/buffer
60 jtL ddH20
These assays were run in 1.5 mL Eppendorf tubes and incubated at 37 oC until being
quenched by reduced temperature. Following quenching, the results were analyzed by HPLC
with a gradient elution from 5% - 30 % B over 15 minutes. For the optimized LC/MS assay, the
reaction was quenched with MeOH and diluted to - 1 nM concentrations (in MeOH) for analysis
(W. Runguphan).
Chemical test reactions of dopamine and 4-HPAA
The continued failure of the assays prompted verification of the aldehyde starting
material by reacting it with dopamine in a chemical test reaction. A literature search gave
several different protocols for reacting dopamine and a range of different aldehydes in Pictet-
Spengler reaction. Each test reaction had 1 mM dopamine and 1 mM 4-HPAA in addition to
buffer or additional solvent. These buffers/solvents included the following:
1. MeOH
2. EtOH
3. 0.1 M NaH2PO 4, pH = 6.0
4. 0.1 M NaH2PO4, pH = 6.5
5. 0.1 M NaH2PO 4, pH = 7.0
6. 0.1 M NaH2PO 4, pH = 7.5
The reactions were run overnight at room temperature and at 37 'C to give twelve different
conditions. In addition, the MeOH, EtOH, 0.1 M NaH2PO4, pH = 6.5, and 0.1 M NaH2PO4, pH
= 7.0 reactions were run at 95 oC for one hour to give sixteen total reaction conditions. Each
reaction was analyzed by HPLC using a gradient elution of 5% B - 30% B over fifteen minutes.
None of the test reactions showed norcoclaurine formation, and reactions run at higher
temperature and higher pH turned brown and precipitated (presumably due to dopamine
oxidation/polymerization).
Cloning tfNCS into pET28-a
The E. coli codon-optimized gene for tfNCS was purchased from Geneart. It was
obtained in a pGA4 plasmid with the ampicillin resistance gene. A restriction double digest was
performed to obtain the gene insert. The target vector pET28-a was also digested to prepare for
ligation. The following reaction mixture was used:
Restriction digest: 19 tL sterile ddH20
5 gtL 10x NEB Buffer 2
20 jiL plasmid DNA (pGA4_tfNCS or pET-28a)
3 gtL NdeI
3 giL EcoRI
The reactions were incubated at 37 'C for 3 hrs. Following incubation, 12.5 AL 5x DNA loading
dye was added and the entire reaction was loaded onto a 1% agarose gel and run at 100 V for 45
minutes. After staining with ethidium bromide for 1 hr, the tfNCS gene fragment and the cut
pET-28a plasmid were isolated using a gel extraction kit (Qiagen).
Following this, the gene fragment was ligated into pET-28a. The following ligation
mixture was successful after several trials:
Ligation: 6 pL tfNCS insert (or H20 in the control)
2 pL freshly cut pET28-a
1 pL 10x T4 DNA ligase buffer
1 pL T4 DNA ligase
This reaction mixture was incubated in a micro-cooler at 20 oC overnight. Following the
ligations, 1 pL of the reaction mixture was added to 55 pL electrocompetent E. coli Top 10 cells
and incubated on ice for 2 minutes. Transformation was achieved using a Bio-rad Micropulser
on the E2 setting. Following transformation, 250 pL SOC media was added and cells were
recovered on ice for -5 min. After recovery, cells were grown shaking at 37 'C for 1 hr. before
the entire 250 pL was plated on LB Agar (Kan) plates. Plates were incubated for -18 hrs. at 37
'C before colonies were picked and grown up in 5 mL liquid cultures with 30 pg/mL Kan.
5 mL liquid cultures were grown overnight shaking vigorously at 37 oC. Plasmid DNA
was isolated using a commercial miniprep kit (Qiagen). An analytical double digest using the
previously described reaction mixture verified presence of the rsSTS gene insert. The sequence
was verified as previously described using the T7 promoter and T7 terminator primers present in
the pET28-a vector.
Expression and purification of tfNCS
The following buffers were used during the Ni-NTA purification of tfNCS:
Lysis Buffer: 50 mM NaH2PO 4  Wash Buffer: 50 mM NaH2PO4
300 mM NaCl 300 mM NaCl
10 mM Imidazole 20 mM Imidazole
pH = 8.0 pH = 8.0
Elution Buffer: 50 mM NaH2PO 4
300 mM NaCl
250 mM Imidazole
pH = 8.0
tfNCS was cultured and isolated similarly to all previously discussed proteins. The
vector pET-28a_tfNCS was transformed into E. coli BL21 (DE3) cells by electroporation. Cells
were grown shaking at 37 "C for 1 hr. before plating on an LB-Agar (Kan) plate and incubation
overnight at 37 "C. A 5 mL LB broth (lx Kan) starter culture was inoculated with cells from a
single colony. This culture was grown overnight shaking at 37 "C. Following overnight starter
culture growth, 1 L LB broth (lx Kan) was inoculated. The 1 L culture was incubated shaking at
37 "C until and O.D. of between 0.5-0.7 was reached. Once O.D. had been reached, the
temperature was dropped to 16 oC and the culture was induced with IPTG. The cultures were
grown overnight shaking at 16 oC. In the morning, cells were harvested by pelleting in the
centrifuge at 4500 rpm for 15 min. Pellets were either used fresh or frozen and stored at -20 oC
until future use.
To obtain tfNCS, cells were lysed using lysozyme and sonication in a manner similar to
that described previously. After lysis, cell debris was pelleted by centrifugation at 13,000 rpm
for 55 minutes. Purification by Ni-NTA affinity chromatography was performed by the standard
procedure. After collection of the flow-through, the column was washed with 100-200 mL wash
buffer to remove weakly or non-specifically bound proteins. Finally, tfSTS was eluted from the
column with 3x 10 mL 250 mM imidazole elution buffer. Fractions were analyzed by SDS-
PAGE.
Activity assays of tfNCSA19_Cterm and tfNCSA19_Nterm
The following reaction mixture was used: to assay the function of the new constructs of
tfNCS:
tfNCSAl9 Assays: 100 pL 200 mM NaH2PO4 pH = 7.00
10 giL 20 mM Dopamine
10 gL 20 mM 4-HPAA (the newly purchased standard)
20 giL tfNCSdl9_Nterm/tfNCSdl 9_Cterm/buffer
60 gLL ddH20
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These assays were incubated at 37 'C until quenching. Reactions were stopped by temperature
quench and analyzed by HPLC utilizing a gradient elution proceeding from 5% B to 30% B (A =
0.1% TFA in H20, B = Acetonitrile) over 15 minutes.
To determine which enzyme was more active, a time course was run using the same
reaction mixture described above. 33 gL aliquots were taken at 2, 4, 6, 8, and 10 minutes and
cold quenched. To aid in quantitation, a naphtylacetic acid (NAA) internal standard was
included. By normalizing to the NAA peak as done with the crSTS kinetic characterization,
errors such as injection error could be corrected for. Plotting the normalized area under the
curve for norcoclaurine did not appear to show any difference between either enzymatic reaction
or the background reactions. This could be remedied by reducing the substrate concentrations,
however this was found to drop the assay below the level of reliable quantitation for the HPLC.
Dynamic Light Scattering of tfNCSA19_Cterm
tfNCSA19_Cterm was obtained in Ni-NTA elution buffer. It was buffer exchanged into
10 mM NaH2PO 4, pH = 7.0 and concentrated to 27.5 mg/mL as measured by A280. Notably, no
precipitation was present even at this high concentration. IM stock solutions were made for each
buffer to be tested and adjusted to the appropriate pH using 4 N NaOH. Before use, the 1 M
stock buffers were diluted to 25 mM concentrations. Using the 25 mM test buffers, the
tfNCSA19_Cterm was diluted to a final concentration of 0.68 mg/mL (A280). No precipitation
was observed in any of the samples. Before acquiring data, all protein/buffer solutions spun at
13,000 rpm for five minutes to remove any dust particles. Samples were equilibrated at room
temperature for 10 minutes.
Data was collected using a DynaPro Titan Dynamic Light Scatterer. A 45 jtL quartz
cuvette was used for each 55 gpL sample. Between colleting data on each sample, the cuvette
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was washed with water and ethanol and dried with dry N2. The experimental parameters
included 10 acquisitions over a 10 s acquisition period (1 s/acquisition). The laser power was
modulated to obtain the optimal value of 800,000 counts per second (or as close as possible).
Once a stable value was reached, data collection was begun. Due to the dilute nature of the
buffers, a H20 solvent model was employed in data processing. The quality of each data
collection was judged on the basis of the auto-correlation function. If the auto-correlation
function was satisfactory, data processing was performed. Data was analyzed using the
Dynamics v6.7.7.9 software. Values of interest were the polydispersity and %mass of the
smallest peak (purity). Buffers with low polydispersity were selected for use in crystallization
screens.
Cloning cjNCS into pET28-a
The E. coli codon-optimized gene for cjNCS was purchased from Geneart. There is no
predicted signal sequence for cjNCS, so a full-length gene was ordered. It was obtained in a
pGA4 plasmid with the ampicillin resistance gene. Following amplification and isolation (by
miniprep) of this plasmid from E. coli Top 10 cells, a double digest was performed to obtain the
gene insert. The target vector pET28-a was digested simultaneously to prepare for the eventual
ligation. The following reaction mixture was used:
Restriction digest: 19 gL sterile ddH20
5 ýLL 10x NEB Buffer 2
20 gL plasmid DNA (pGA4_cjNCS or pET-28a)
3 [L NdeI
3 gL EcoRI
The reactions were incubated at 37 'C for 3 hrs. Following incubation, 12.5 gL 5x DNA
loading dye was added and the entire reaction was loaded onto a 1% agarose gel and run at 100
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V for 45 minutes. After staining with ethidium bromide for 1 hr, the cjNCS gene fragment and
the cut pET-28a plasmid were isolated using a gel extraction kit (Qiagen).
Following this, the gene fragment was ligated into pET-28a. The following ligation
mixture was successful after several trials:
Ligation: 6 giL cjNCS insert (or H20 in the control)
2 tL freshly cut pET28-a
1 iL 10x T4 DNA ligase buffer
1 jtL T4 DNA ligase
This reaction mixture was incubated at 18 oC overnight. Following the ligations, 1 jtL of
the reaction mixture was added to 55 giL electrocompetent E. coli Top 10 cells and incubated on
ice for 2 minutes. Transformation was achieved using a Bio-rad Micropulser on the E2 setting.
Following transformation, 250 gL SOC media was added and cells were recovered on ice for -5
min. After recovery, cells were grown shaking at 37 oC for 1 hr. before the entire 250 gL was
plated on LB Agar (Kan) plates. Plates were incubated for -18 hrs. at 37 'C before colonies
were picked and grown up in 5 mL liquid cultures with 30 pg/mL Kan.
5 mL liquid cultures were grown overnight shaking vigorously at 37 oC. Plasmid DNA
was isolated using a commercial miniprep kit (Qiagen). An analytical double digest using the
previously described reaction mixture verified presence of the rsSTS gene insert. The sequence
was verified as previously described using the T7 promoter and T7 terminator primers present in
the pET28-a vector.
Expression and purification of cjNCS
The following buffers were used during the purification of cjNCS for assays and
crystallization:
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Lysis Buffer: 50 mM NaH2PO4  Wash Buffer: 50 mM NaH2PO4
300 mM NaCl 300 mM NaCl
10 mM Imidazole 20 mM Imidazole
pH = 8.0 pH = 8.0
Elution Buffer: 50 mM NaH2PO4  MonoOA/SE200: 50 mM Tris-HCl
300 mM NaCl 0 mM NaCl
250 mM Imidazole pH = 7.5
pH = 8.0
MonoQ Buffer B: 50 mM Tris-HCl
1 M NaC1
pH = 7.5
cjNCS was cultured and isolated similarly to crSTS and rsSTS. The vector pET-
28a_cjNCS was transformed into E. coli BL21 (DE3) cells by electroporation. Cells were grown
shaking at 37 'C for 1 hr. before plating on an LB-Agar (Kan) plate and incubation overnight at
37 TC. A 5 mL LB broth (lx Kan) starter culture was inoculated with cells from a single colony.
This culture was grown overnight shaking at 37 'C. Following overnight starter culture growth,
1 L LB broth (lx Kan) was inoculated. The 1 L culture was incubated shaking at 37 'C until and
O.D. of between 0.5-0.7 was reached. Once O.D. had been reached, the temperature was
dropped to 16 oC and the culture was induced with IPTG. The cultures were grown overnight
shaking at 16 oC. In the morning, cells were harvested by pelleting in the centrifuge at 4500 rpm
for 15 min. Pellets were either used fresh or frozen and stored at -20 oC until future use.
To obtain cjNCS, cells were lysed using lysozyme and sonication in a manner similar to
that described. After lysis, cell debris was pelleted by centrifugation at 13,000 rpm for 55
minutes. Purification by Ni-NTA affinity chromatography was performed as described for
crSTS. Resin was washed with lysis buffer before use to remove ethanol and equilibrate the
column. The resin was added to the supernatant in the 50 mL tubes and incubated with gentle
shaking at 4 'C for 1-2 hrs. Following this incubation period, the mixture was added to the
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column and the flow-through was collected. After collection of the flow-through, the column
was washed with 100-200 mL wash buffer to remove weakly or non-specifically bound proteins.
Finally, cjSTS was eluted from the column with 3x 10 mL 250 mM imidazole elution buffer.
Fractions were analyzed by SDS-PAGE. Elution fractions were concentrated and buffer
exchanged into 50 mM Tris-HCI before further use.
cjNCS was further purified by MonoQ anion exchange chromatography and SE200 size
exclusion chromatography using the FPLC. Fractions were collected and analyzed by SDS-
PAGE.
Bradford assay of cjNCS
To verify the value for cjNCS concentration obtained by A280, a Bradford assay was
performed using the BioRad Bradford Assay Kit. A 1 mg/mL BSA standard solution was made.
The actual concentration of this standard was shown to be 0.973 mg/mL (using EBSA = 0.67
(mg/mL)'). To generate a standard curve, eight different serial dilutions were made from this
stock to give a total of nine data
Figure 3.14 - Bradford Assays Standard Curve points for the curve. Three protein
cCS Bradford Standard Curve
solutions were also analyzed -
1.2
v - 1.8647x +
undiluted protein, 2x diluted
protein, and 10x diluted protein.
To generate the curve and
measure the concentrations, the
concentrated reagent was diluted
0 ------------------------- - ;
0 0. .4 e.6 0.3 1 1.2 per the manufacturers instructions
c.-------- (m-/m-.)
(one part reagent, four parts water).
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10 gIL of each sample was added to a 96 well microtiter plate (Nunc) followed by 200 .tL dilute
reagent. The assay was developed in the dark for 10 minutes before the absorbencies were
recorded using a Varian 50 MPR microplate reader.
Cloning new constructs of cjNCS
The primers used to clone cjNCS with an N-terminal FLAG tag are as follows:
N-terminal: CCATGGGCGATATAAAAGATGATGATGATAAACCGATGAGCAAAAACCT
GACCGGCGTG
C-terminal: TTGTCGACGGAGCTCGAATTCTTATTACAGTTTCAT
These primers were ordered and obtained from Integrated DNA Technologies. The following
reaction mixture was used for the PCR reaction:
PCR reaction: 5 giL 10x buffer
1.5 gL 10 mM dNTP mix
2 jtL template DNA (pET28-a_cjNCS)
1 gL N-terminal primer
1 jtL C-terminal primer
38.5 jtL dd H20
1 gL High Fidelity Polymerase
These components were mixed in individual PCR tubes. PCR was done using a Stratagene
RoboCycler Gradient 96 with the following program:
# of Cycles Course
1 120 s, 95 'C
33 30 s, 95 'C
1 min, 52-61 oC
1.75 min, 68 'C (1 min per kb plasma length)
Hold Hold at room temperature
After the PCR was complete, each sample was purified using a Qiagen PCR clean-up kit
and analyzed by 1% agarose gel electrophoresis. Samples that showed DNA fragments of the
appropriate sized were selected and sub-cloned into a pGEM-T Easy transfer vector. The
reaction mixture for pGEM-T Easy ligation is as follows:
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pGEM-T Ligation: 5 gL 2x ligation buffer
1 gL pGEM-T Easy vector
3 gL cjNCS-FLAG
1 gL T4 DNA ligase
The ligations were incubated at 4 oC overnight before transformation into
electrocompetent E. coli Top 10 cells and plated as previously described. White colonies from
the pGEM-T Easy ligation were selected and grown in liquid culture. Plasmid was harvested
from the cells by miniprep and analyzed by a restriction double digest to verify the presence of
the cjNCS-FLAG insert. Successful samples were submitted for sequencing using the T7
promoter and SP6 promoter primers. Sequencing revealed a mutation in the FLAG sequence.
The following primers were designed to remedy the mutation:
5'-3': ATGGGCGATTATAAAGATGATGATGATAAAGGCATGAGCAAAAAC
3'-5': GTTTTTGCTCATGCCTTTATCATCATCATCTTTATAATCGCCAT
These primers were used with a Stratagene QuickChange Site-Directed Mutagenesis kit
using procedures previously described.
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